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AML  Acute myelogenous leukemia 
B-CLL  Chronic lymphocytic leukemia 
BCR  B cell antigen receptor 
DAPI  4’,6’-diamidino-2-phenylindole 
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ECM  extracellular matrix 
EDTA  Ethylenediaminetetraacetic acid 
EGFP  Enhanced green fluorescent protein 
FAK  Focal adhesion kinase 
G3BP  Ras-GAP SH3 domain binding protein 
GAPDH Glyceraldehyde phosphate dehydrogenase 
Grb7  Growth factor receptor-bound protein 7 
GST  Glutathione S-transferase 
ITAM  Immunoreceptor tyrosine-based activation motif 
Lyn  Yamaguchi sarcoma viral oncogene homolog 
MTOC Microtubule organizing center 
mTOR Mammalian target of Rapamycin 
NF B  Nuclear factor kappa B 
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ShRNA Small hairpin RNA 
SH2  Src homology 2 
SH3  Src homology 3 
Src  Rous sarcoma oncogene cellular homolog 
Syk  Spleen tyrosine kinase 
TIA-1  T-cell intracellular antigen-1 
TIAR  TIA-1-related protein 
VCP  Valosin-containing protein 
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 The Syk protein-tyrosine kinase, a well-characterized modulator of 
immune recognition receptor signaling, also plays important, but poorly 
characterized, roles in tumor progression, acting as an inhibitor of cellular motility 
and metastasis in highly invasive cancer cells. Multiharmonic atomic force 
microscopy (AFM) was used to map nanomechanical properties of live MDA-MB-
231 breast cancer cells either lacking or expressing Syk. The expression of Syk 
dramatically altered the cellular topography, reduced cell height, increased 
elasticity, increased viscosity, and allowed visualization of a more substantial 
microtubule network. The microtubules of Syk-expressing cells were more stable 
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to nocodazole-induced depolymerization and were more highly acetylated than 
those of Syk-deficient cells. Silencing of MAP1B, a major substrate for Syk in 
MDA-MB-231 cells, attenuated Syk-dependent microtubule stability and reversed 
much of the effect of Syk on cellular topography, stiffness, and viscosity. This 
study illustrates the use of multiharmonic AFM both to quantitatively map the 
local nanomechanical properties of living cells and to identify the underlying 
mechanisms by which these properties are modulated by signal transduction 
machinery. 
 Proteomic analyses of Syk-binding proteins identified several interacting 
partners also found to be recruited to stress granules. Treatment of cells with 
inducers of stress granule formation leads to the recruitment of Syk to these 
protein-RNA complexes. This recruitment requires the phosphorylation of Syk on 
tyrosine and results in the phosphorylation of proteins at or near the stress 
granule. Grb7 is identified as a Syk-binding protein involved in the recruitment of 
Syk to the stress granule. This recruitment promotes the formation of 
autophagosomes and the clearance of stress granules from the cell once the 
stress is relieved, enhancing the ability of cells to survive the stress stimulus. 
1 





 Thirty-six years have passed since the discovery of tyrosine 
phosphorylation.  It has emerged as a fundamentally important mechanism of 
how cells communicate with each other and their surroundings.  This discovery 
has led to our understanding today of the tyrosine kinome, which represents10-
15% of the total protein kinase genes in humans, yet plays a major role in many 
disease states including cancer.1,2  Our laboratory has contributed to the tyrosine 
kinome through the discovery of Syk (spleen tyrosine kinase), which we isolated 
from bovine thymus while another group isolated it shortly thereafter from porcine 
spleen.3,4  The Syk family consists of only two proteins, Syk and zeta-chain-
associated protein of 70 kDa (ZAP-70).  Syk is crucial for B development and 
immune receptor function particularly during B cell receptor engagement, while 
ZAP-70 has an important role in T cell development and function.5-9   
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 Syk is 72 kDa non-receptor tyrosine kinase consisting of two Src 
homology 2 (SH2) domains separated by linker A, while linker B separates the 
SH2 domains from the catalytic domain (Figure1.1).  Classical activation of Syk is 
achieved either by recruitment to immune recognition receptors through its two 
SH2 domains, which dock with phosphorylated immunoreceptor tyrosine-based 
activation motifs (ITAMs) that contain the consensus sequence YxxI/Lx6-12YxxI/L 
located on the receptor, or by phosphorylation on tyrosine.10-12 Phosphorylation 
of several tyrosines throughout the kinase not only tunes its activity, but also 
impacts its localization to various cytoplasmic structures and organelles. 
Phosphorylation on tyrosine 130 releases Syk from ITAM-bearing receptors and 
recruits Syk to other locations, including the centrosome where it phosphorylates 
a number of centrosomal proteins.13,14 Phosphorylation on tyrosine 317 inhibits 
Syk’s activity by promoting its interaction with the ubiquitin ligase c-Cbl.15-19 
Phosphorylation within the linker B region on tyrosines 324 and 346 promotes 
protein-protein interactions involving many proteins including PLC- , Vav-1, Vav-
2, and Grb2.20-21  These proteins can bind to one or both phosphotyrosines.  We 
also have observed Syk’s interaction with Grb7, an adaptor protein, via these two 
tyrosine residues (see Chapter 5).  Tyrosines 519 and 520 are found within the 
activation loop of the catalytic domain.  Both tyrosines are phosphorylated in vitro 
and in B cells when the BCR is engaged.20-21  Mutations to phenylalanine on both 
residues have little effect on the catalytic activity.22  This could be due to the 
orientation of them within the active site.  This orientation may still allow ATP to 
have access.  There are three C-terminal tyrosines of Syk (Y623, Y624, and 
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Y625).  They are phosphorylated at relatively low initial rates.20-21 It is thought 
that these tyrosines can provide docking sites for “signalosomes” to be built on.  
For example, Y624 is surrounded by pYYDV residues that resemble a binding 
site for SH2 domain of adaptor protein of the SLP-family including BLNK/SLP-
65.23 Formation of this protein complex yields activation of PLC 2 that activated 
inositol triphosphate and diacylglycerol resulting in protein kinase C activation 
and leading to a sustained calcium influx.    
  
1.2 The role of Syk in tumorigenesis 
 A role for Syk in non-hematopoietic epithelial cells is emerging, particularly 
in carcinomas where Syk has a convoluted role of being either a tumor 
suppressor in some cells or a tumor promoter in others.24-29 A review of Syk and 













1.3 Efforts to understand Syk’s dual role in tumorigenesis 
 In an effort to understand the dual role of Syk in tumorigenesis, we 
conducted a mass spectrometry analysis to identify substrates and interacting 
proteins.  The identified proteins helped up to identify candidate pathways for the 
dual roles.  We identified a number of proteins that are linked to motility and 
stabilization of cellular cytoskeleton.  This pathway supported the hypothesis that 
Syk is a tumor suppressor.  We also identified a number of proteins involved in 
mRNA translation and mRNA sequestration.  These proteins appeared to be 
linked to stress granules, which are hypothesized to play a survival role in 
cancer.  Interaction of Syk with stress granule machinery supported the 
hypothesis that Syk is a tumor promoter through its modulation of cellular 
survival.  In the next sections I will address each of the candidate pathways: 
motility and survival.   
 
1.3.1 Syk as a tumor suppressor negatively effects motility  
 The effects of Syk on cellular motility and invasion have been extensively 
characterized.  In breast epithelial cell line, MCF10A, knockdown using shRNA 
targeting Syk results in an increase of motility, invasion, and growth in soft 
agar.26 It has also been hypothesized Syk can inhibit the transition from epithelial 
to mesenchymal phenotype before metastasis occurs.  Comparing gene 
expression trends resulting from silencing of Syk expression confirms the loss of 
epithelial gene products and the increased expression of genes characteristic of 
mesenchymal phenotype.  Syk has been included in the EMT gene core 
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signature, and its expression being modulated when EMT-inducing transcription 
factors are upregulated.31 It appears that Syk’s catalytically activity is responsible 
for its negative motility effects during tumorigenesis.  When catalytically inactive 
form of Syk was expressed in breast epithelial cell line, MCF7, motility was 
enhanced compared to wild-type Syk.32 Similar results were observed in K-Ras 
addicted pancreatic carcinomas where the knockdown of Syk expression 
resulted in the loss of E-cadherin expression, which is also typically observed 
when cells transition to mesenchymal phenotype during EMT.33  
 One of the substrates that were identified in our mass spectrometry 
analysis was MAP1B protein.  This protein has been extensively studied in the 
regulation of cellular cytoskeleton.  We decided to characterize whether Syk 
inhibits motility through the MAP1B pathway.   
 
1.3.2 MAP1B 
 MAP1-family proteins are microtubule-associated proteins (MAPs) that 
bind to the microtubule lattice.34 The family consists of four members: MAP1A, 
MAP1B, MAP2, and MAP1S.  My research specifically focuses on MAP1B.  This 
protein is a critical regulator of microtubule dynamics. It is a large protein, 
displaying the highest expression in the brain.35 It can either function as a full-
length protein or can be cleaved to form a light and heavy chain.34 The light chain 
interacts with stress fibers.36 In our mass spectrometry analysis identified over 17 
Syk-dependent phosphorylation sites on MAP1B.  This is intriguing because 
many of these tyrosines could regulate MAP1B binding to microtubules, and/or 
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association with other proteins to build scaffolds on the microtubules. MAP1B is 
primarily known for its influence on microtubule dynamics, enhancing their 
assembly rates.34 Its N-terminal microtubule-binding domain associates with 
microtubule polymers.  It has also been found that MAP1B can modulate the 
shape of microtubules by making them longer and more flexible. It is 
hypothesized that this could also influence the spatial distribution of microtubules 
throughout the cytoplasm.34 Although the majority of the research on MAP1B has 
been carried out in neurons, it was shown that MAP1B has the same effect in 
fibroblasts.37 It enhanced both the stability of microtubule polymers against 
depolymerization agents, and enhanced the acetylation of polymers; a sign of 
stable microtubules.   
 
1.3.3 Cytoskeletal networks and motility 
 Cytoskeletal networks are vital components of cell shape and function. 
They are involved in but not limited to important cellular processes including cell 
division, differentiation, spatial organization of organelles, sensing extracellular 
cues in the environment, migration, and invasion.38 The cytoskeleton is 
composed of actin filaments, microtubules, and intermediate filaments. There are 
overlapping functions among the three components because they rely on each 
other to orchestrate complex changes to the physical properties of cells.38 For 
example, although the actin cytoskeleton was first shown to have a significant 
role in migration, microtubules also play a significant role.  Several studies have 
shown that microtubules facilitate focal adhesion turnover specifically during the 
8 
disassembly process.39,40 Without this turnover, cells cannot detach from the 
extracellular matrix.  For example, MAP4K4 kinase has been shown to regulate 
focal adhesion turnover.  It interacts with the microtubule polymer and EB2, a 
plus-end tracking protein that is found on the tips of growing microtubule 
polymers.40 Delivery of MAP4K4 by microtubules is critical for integrin 
internalization, which this kinase guides once it is delivered to focal adhesions.40  
 There are also three well-known GTPases that have been reported to 
contribute significantly to motility: Rac1, CDC42, and RhoA.  These proteins 
belong to the Ras superfamily.  RhoA is involved in the regulation of stress fibers 
and focal adhesion turnover.41  Rac1 is involved in membrane ruffling.40  Cdc42 
aids in filopodia formation.41  RhoA and Rac1 proteins play antagonistic roles and 
there is an intricate crosstalk between the two proteins.  For example, for 
lamellipodia formation Rac inhibits Rho.41  Whereas in the lamellum and the rear, 
Rho inhibits Rac.41  It has also been shown that Rac1 drives oriented 
mesenchymal motility during tumor progression, while RhoA activation is 
responsible for amoeboid motility, which many times cells utilize this non-oriented 
movement during invasion.41-43 
 Understanding how each cytoskeletal group contributes individually and 
collectively to motility is important because if or when cancer arises, we will 
better understand how the cytoskeleton network contributes to the cancer state 
and how to target cytoskeletal features that promote carcinogenesis.   
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 F-actin is composed of G-actin monomers that reversibly polymerize to 
form filaments.38 These filaments are thin, flexible fibers approximately 7 nm in 
diameter.44 F-actin filaments are organized into bundles forming actin networks.  
F-actin filaments are abundant beneath the plasma membrane and provide 
mechanical support for the cell.38  Meshwork of F-actin filament bundles play an 
important role in the formation and function of lamellipodia during motility.  The 
actin cytoskeleton at the front of the cell is constantly going through a 
treadmilling, which involves polymer depolymerization and then repolymerization. 
This allows the membrane to stretch and for lamellipodia to spread as the cell 
generates enough force to propel forward.46  Assembly of actin filaments into 
stress fibers also helps to reinforce cell morphology.45 
 Intermediate filaments, as the name implies, have diameters in the range 
of 10 nm, falling in between the sizes of actin filaments and microtubules.44 
Intermediate filaments are known for their mechanical strength and contributions 
to cellular morphology rather than motility.  They are composed of hard and soft 
keratins compared to actin and microtubules, which are made of monomers 
joined together.38,47 Each intermediate filament monomer consists of an alpha 
helical rod domain.  The dimers are formed when rods coil around each other.47 
These dimers stagger together to form tetramers that make up the filament.  
These filaments are apolar-having no distinct ends.47 Intermediate filaments are 
organized into five groups with expression varying depending on the cell type.  
For example, filaments in epithelial cells are largely composed of keratins while 
fibroblasts, smooth muscle cells, and white blood cells use vimentin.47  
10 
 Microtubules are composed of dimers of alpha and beta tubulin subunits 
joined together in a head-to-tail fashion to form hollow pipes approximately 25 
nm in diameter.36 Microtubules are the biggest filaments when comparing 
filaments’ diameters.  They are organized in a polar fashion with the minus-end 
located at the microtubule organization center (MTOC) or centrosome.30 This is 
where nucleation of microtubule polymers takes place.  The plus-end spans out, 
and is in dynamic transition between free tubulin heterodimers (shrinkage) and 
polymers (growing).30  Microtubules are responsible for many critical cell 
functions including motility, intracellular transport, and chromosome segregation 
during mitosis.30   
 
1.3.4 Microtubule cytoskeleton and critical proteins involved in cancer cell motility 
 Motility has an important role in wide-variety of physiological outcomes 
including immune surveillance, wound healing, and cancer dissemination.48-52 
Typically external cues such as chemotactic gradients initiate and influence the 
direction of migration.  Migration occurs in a four-step chronological order with 
the first two steps overlapping: protrusion, adhesion, contraction, and retraction 
(Figure 1.2).53  Initiation of each of these steps requires a significant proportion of 
the cytoskeleton to rearrange and eventually efficiently aid cell’s disconnect from 
the extracellular environment including basement membrane and cell-cell 
contacts.   This section will focus on migration in relation to cancer dissemination. 
 Protrusion is the first step of migration.  Once the cell senses the presence 
of a chemotactic attractant, polarization towards the extracellular cue is initiated.  
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Actin filaments bundle towards the leading edge of the cell forming a protruding 
bleb that will become the lamellipodium.45,53   This step also relies on the support 
of microtubules.  Studies have shown that cells treated with nocodazole, a 
microtubule-destabilizing agent, experience a loss of polarization.54  Microtubules 
orient themselves along the horizontal axis of the cell towards the leading edge.  
The microtubule organization center (MTOC) reorientation is dependent on the 
organization of microtubules.55-57 It is thought that accumulation of dynein motor 
proteins on microtubule polymers generates a pulling force to orient the MTOC 
toward the protrusion resulting in the MTOC being in front of the nucleus.58    
During this stage, microtubules also provide mechanical support by bearing high 
compressive loads. Many microtubule-associated proteins and microtubule plus-
end proteins (+TIPS) contribute to the polarization and maintenance of 
microtubule dynamics throughout the formation of lamellipodium.  Specifically, 
microtubules rely on Rho family proteins.  For example, polymerized 
microtubules activate Rac to promote formation of lamellipodia.59 Microtubules 
also support trafficking of membrane vesicles, recycling endosomes, delivering 
mRNAs to the leading edge to helping to maintain signaling pools there.  For 
example, in breast cancer there is a significant increase in the expression of Rho 
GTPases whose levels are barely detectable in normal mammary tissue.59 In 






 While the protrusion phase is occurring, it is necessary for adhesion to 
stabilize it.  Integrins mediate focal adhesions.  Microtubules have been show to 
control formation and maturation of focal adhesions and deliver integrins to the 
leading edge.60 For example, during hypoxia in MDA-MB-231 cells, Rab11 
protein becomes expressed.  Rab11 regulates recycling of endosomes of integrin 
beta 1 and vesicle transport.61,62  It also has been shown to transport integrin 
6 4 to the plasma membrane.63  In addition, hypoxia promotes an increase in 
6 4 expression that relies on stable microtubules.63  When cells are treated with 
the microtubule-destabilizing agent, colchicine, Rab11 trafficking is blocked and 
this inhibits focal adhesion turnover.63  
 Contraction is the third step of migration, which guides the disassembly of 
focal adhesions at the rear edge, and it is directly followed by retraction, pushing 
the cell forward.53 Microtubules have been shown to be important for these last 
two processes.  One possible mechanism could be that microtubules contribute 
indirectly to contractility through the sequestration of p190RhoGEF and GEF-
H1.64 These proteins become inactivated when they associate and bind to 
microtubules.  This interaction promotes initiation of contraction.64 Retraction of 
the rear edge is also guided by microtubules.  Treatment of cells with low doses 
of nocodazole promotes an increase in adhesion to the extracellular matrix.  
Microtubules are also needed to release focal adhesions at the rear edge in 




1.3.5 Mechanical properties of cancer cells and detecting changes using AFM 
 Atomic force microscopy (AFM) is becoming a promising tool to study 
cytoskeletal features.   This is particularly useful to the cancer biology field 
because during tumor formation while being confined to a restricted space, cells 
experience many forces including compression forces and tension forces as they 
transition through EMT.67 To adapt to this environment, cancer cells remodel 
their cytoskeletal networks.  For example, stiffer extracellular matrix from cells 
excreting factors into their extracellular environment can induce 5 integrin 
production helping the cell to adhere to combat the tension forces applied by a 
much stiffer extracellular matrix than what it normally is accustomed to.67,68  Once 
the cancer cell metastasizes, cells experience hydrostatic pressure when 
circulating through the lymphatic system.66  It is hypothesized that cancer cells 
are exposed to different mechanical forces compared to normal cells leading to a 
much different mechanical signature that could be distinguished by comparing 
cytoskeletal networks between cancer and normal cells. 
 AFM is a useful technique to study physical properties of substances 
because it can provide a mechanical signature of nonliving and living systems 
(Figure 1.3).69  This technique uses force measurements by detecting the force 
that arises from a probe, called the tip, coming in contact with the sample.69  The 
cantilever is attached to the tip and senses any movement changes of the tip as 
the tip scans over a sample’s surface.  The tip can either come in contact with 
the entire surface or tap on various locations on the sample to get a general 
representation of the properties of the sample.  Typically, the tapping method is 
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much better for soft samples compared to scanning.69 AFM can be utilized with 
water, buffers, or other media surrounding the sample.69 It also has the ability to 
generate 3D surface topographical images in conjunction with light or confocal 
microscopy. It can also capture the biophysical properties of samples including 
elasticity, adhesion, stiffness, friction, and force-volume measurements.69 A 
number of researchers have utilized AFM to study cellular morphology, and it is 
becoming much more popular in the cancer biology field. 
 Cancer research primarily has focused on genetic and biochemical 
screening techniques to detect and predict patient outcomes.  AFM has slowly 
been utilized to supplement and possibly replace current diagnostic strategies.  
For example, the mechanical properties of the MCF-10A cell line were compared 
to those of the MCF7 cell line.  MCF7 cells were less stiff as compared to the 
benign MCF10A cell line.70 This change was attributed to a reduction in actin 
filaments in the MCF7 cells.70 It was hypothesized that cytoskeletal changes 
brought about by the malignant transformation contributed to enhanced migration 
and metastasis based on the mechanical signature that was derived.70  In 
another study, samples were obtained from pleural effusions of patients with 
lung, breast, and pancreatic cancers.  Cancer cells from the effusions were 
approximately seventy percent softer than normal cells in the same fluid.71,72  In 
another study, AFM was used to record changes in morphology from the 
following cell lines exposed to anti-cancer drugs: human cervical carcinoma, 
human hepatocellular liver carcinoma, and rat glioma.  Anti-cancer drugs, 
colchicine and cytarabine, were used to assess morphological changes in cell 
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lines treated with and without these drugs.73 Both of these drugs have been 
shown to affect cytoskeletal networks by disrupting microtubule networks.73 In 
response to treatment with either drug, the cells displayed an increase in the 
fluctuations of the surface components of the cell membrane, an increase in 
shrinkage, and/or appearance of pores.73 This example illustrates how AFM can 
capture morphological changes and how it can be used to study interactions 
between cells and anti-cancer drugs.  Changes in the mechanical properties of 
cells as they go through the transformation process could be utilized as a useful 
biomarker when tracking progression of a particular disease.   
 
1.4. Syk as a tumor promoter 
 To better understand the functional role of Syk in cancer, we conducted a 
series of proteomic analyses to identify substrates and interacting partners.  
Among the binding partners we identified several proteins involved in mRNA 
metabolism and proteins that are known to associate with SGs, including G3BP, 
eIF2, VCP, eIF1A, and HSP70.74,75 These findings raised an interesting question 
as to whether Syk also functionally associates with stress granules.   
 
1.4.1 Stress granule composition and formation 
 Stress granules are cytoplasmic, non-membranous foci consisting of poly 
(A) mRNAs and binding proteins, elongation initiation factors, 40S ribosomal 
subunits, and other signaling molecules; although their composition can vary 
depending on the stress.76 Their formation is temporally regulated, specifically 
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being limited to the initiation phase of translation when the mRNA message is still 
bound to the 40S ribosomal subunit (Figure 1.3).77  Formation is promoted with 
drugs that block translation initiation including puromycin, and inhibited with 
drugs such as cycloheximide that block translation elongation.78 Sodium arsenite, 
glucose deprivation, proteasomal inhibition, and heat shock are some of the 
typical stimuli that promote SG assembly.79-82   These stimuli typically activate the 
stress response pathway via phosphorylation of eIF2 on serine residue 51 by 
stress-sensing serine/threonine kinases GCN2 (activated by glucose 
deprivation), HRI (monitors ROS production), PERK (ER stress sensor), and 
PKR (activated with viral infections and heat shock).77  Phosphorylation of eIF2 
converts it into a competitive antagonist of eIF2B, which promotes the exchange 
of GDP for GTP in the eIF2-GTP-tRNAMet ternary complex during translation.77 
This depletes the GTP stores of the ternary complex and inhibits translation.  
RNA binding proteins TIAR, TIA-1, and G3BP utilize their self-aggregation 
domains to promote aggregation and nucleation of factors and thus are 
considered an integral part of the formation process.77,83 Overexpression and 
phosphorylation of G3BP has also been shown to induce stress granule 








1.4.2 Stress granules and chemotherapeutics 
 Recent evidence suggests that stress granules have an important role in 
cancer and neurological diseases making them interesting protein aggregates to 
study.76 The role in cancer appears to be through the modulation of prosurvival 
pathways.  During the initiation of tumor formation, cells experience many 
significant changes in the local environment.  This tumor microenvironment and 
the response to stress do to changes within the microenvironment are important 
to cancer development and the cellular response to chemotherapeutics.  For 
example, a number of chemotherapeutic agents have been shown to induce 
stress granule formation leading to resistance or apoptosis depending on the 
cancer cell and/or therapeutic target.  Both Bortezomib (PS341/Velcade), a drug 
used to treat mantle cell myeloma and multiple myeloma, and 5-fluorouracil (5-
FU), a drug used to treat breast, colorectal, head and neck cancer, promote the 
formation of stress granules, although by different mechanisms.77,84,85  Treating 
colon, cervical, and lung cancer cell lines with Bortezomib induces resistance to 
apoptosis via formation of stress granules by activation of HRI kinase pathway.84   
To assess whether HRI was responsible for Bortezomib –induced resistance, 
HRI was depleted using siRNA directed against HRI.  Cells failed to form stress 
granules and undergo apoptosis.84 5-FU induces assembly of stress granules via 
activation of PKR kinase, and this leads to stress granule assembly.85 Other 
cancer treatment methods can induce formation of stress granules but production 
of these specific stress granules leads to survival rather than apoptosis.  For 
example, sodium selenite promotes the production of reactive oxygen species 
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(ROS) resulting in ER stress and activation of eIF2  leading to formation of 
stress granules in prostate cancer and osteosarcoma cell lines.86 These 
particular stress granules are functionally distinct from the canonical ones 
because they promote apoptosis rather than survival.  Further studies will need 
to focus on dissecting the mechanisms by which stress granules either drive cells 
to apoptosis or survival.   
 
1.4.3 Stress granules and cancer survival mechanisms 
 How stress granules modulate prosurvival pathways is still unclear.  One 
hypothesis is that stress granules selectively regulate the expression of proteins 
involved in cell survival by translationally silencing their mRNAs. Another 
hypothesis is that they increase local concentration signaling molecules and 
potentially deplete the bulk of these molecules in the cytoplasm.  Another role for 
stress granules is that their formation during stress conditions helps to maintain 
effective translation by maintaining proper ratio of mRNA pool in the 
cytoplasm.77,87  
 Several studies have shown that stress granules can inhibit apoptosis and 
modulate prosurvival signal transduction cascades through the sequestration and 
accumulation of signaling components into insoluble puncta.  For example, cells 
utilize the mTORC1 complex for growth and survival.88 This complex is 
composed of seven core components: mTOR (serine/threonine kinase), raptor 
(scaffolding protein), mLST8 (unknown activity), pras40 (inhibitor), deptor 
(inhibitor) and tti1/tel2 (scaffolding proteins).88  Oxidative stress can lead to 
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mTORC1 activation.88  Formation of stress granules activates an inhibitor of the 
mTORC1 complex under stress conditions, astrin, leading to sequestration of the 
raptor component of the mTORC1 and its accumulation in stress granules.  The 
absence of raptor inhibits mTORC1 hyper-activation-induced apoptosis.89 Stress 
granule inhibition of apoptosis has also been shown to involve the mitogen-
activated protein kinase (MAPK) pathways.90 Environmental stress can trigger 
MTK1 activation.  Optimal activation occurs when Rack1 binds to MTK1 
producing an inactive pre-formed dimer to which GADD45 binds.  This and 
facilitates MTK1 activation leading to an apoptotic response through the p38/JNK 
MAPK pathway.  Rack1 has been shown to be sequestered into stress granules 
resulting in the inhibition of MTK1 and thus downregulation of apoptosis.90 Both 
examples support the hypothesis that stress granules are able to sequester 
signaling factors, and modulate signal transduction outcomes in the cytoplasm.   
 
1.4.4 Stress granule disassembly and autophagy 
 Stress granules are dynamic foci varying in protein composition depending 
on the type of stimuli they encounter.  These foci also range in size and formation 
rates.   Once a stress stimulus is alleviated, recovery results in the return of bulk 
protein synthesis and translation of individual mRNAs resulting in the 
disassembly of these microscopically visible puncta.  Overexpression of a few 
RNA-binding proteins such as Staufen also can promote disassembly.91  Staufen 
helps to stabilize the mRNA-polysome interaction, but the mechanism of 
clearance is still elusive.91  Another factor that contributes to clearance is 
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disruption of protein-protein interactions within the granules.  Grb7 is a well-
characterized adaptor protein that has been shown to be recruited to stress 
granules.92 Interestingly, our laboratory has validated Grb7 to be an interacting 
partner of Syk.  Phosphorylation of Grb7 by focal adhesion kinase (FAK) in stress 
granules promotes their disassembly.93    The exact mechanism of disassembly 
is still unclear as to whether the aggregates dissolve, break apart, or are 
removed/cleared by other cellular machinery.   
 Recent evidence has suggested autophagy is one of the mechanisms by 
which stress granules are cleared.  Autophagy is a self-destructive process when 
parts of the cytoplasm and intracellular organelles including protein aggregates 
are enveloped into autophagocytic vacuoles, called autophagosomes. These 
vacuoles can dock and fuse with lysosomes for degradation to take place.94 
Autophagy can be induced by a number of different stress stimuli, including 
nutrient depletion, ER stress, and pathogen-induced molecular patterns.  One 
marker of autophagy is microtubule-associated protein 1A/1B-light chain 3 (LC3).  
The cytosolic form of LC3 is referred to as LC3-I.  During autophagosome 
formation, LC3-I becomes covalently linked to phosphatidylethanolamine, and is 
integrated into the autophagosome membrane.  When this integration occurs, 
LC3 is referred as LC3-II.  The level of conversion from LC3-I to LC3-II serves as  
as a useful marker for autophagy.95     
 It has been shown in literature that enhanced autophagy reduces the 
number of stress granules in cells.96-99  In one study, Buchan et al. screened 
4,249 nonessential gene deletions in yeast and identified mutations that altered 
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stress granule assembly.  Several of the identified mutations appeared to disrupt 
autophagy and this disruption led to an increase in stress granules.98  Valosin-
containing protein, VCP, was shown to be a critical component of autophagy-
mediated stress granule clearance.97,98 Knockdown of VCP inhibits stress 
granule clearance.  VCP is a critical component of the ubiquitin-dependent 
protein quality control system.  Upregulation of VCP promotes autophagy and 
correlates with poor prognosis of many cancers.  These data support our 
observation that during stress granule clearance, Syk-expressing cells clear 
stress granules at a faster rate compared to cells that lack Syk.  In this system, 
we observe an upregulation of autophagy correlated with lower numbers of 
stress granules.  Further studies need to be undertaken to investigate how 
autophagy and its components degrade stress granules.  
 
1.5 Perspectives 
 The exact role of Syk in cancer is unclear as its role as a tumor 
suppressor or a tumor promoter is context dependent and varies between cancer 
cell types.  Even though its role is cancer-type dependent, we do see Syk 
displaying a prosurvival role in most cancer types.  The biological functions of 
Syk arise from its ability to influence down-stream signal transduction pathways 
involving cellular proliferation, division, migration, invasion, apoptosis, and 
transcription.  In breast cancer, Syk has been shown to display a tumor 
suppressor phenotype via inhibition of migration and invasion.  In addition, Syk 
has been shown to interact with tubulin, the major component of microtubules.  It 
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would be valuable to understand the underlying mechanisms by which Syk 
inhibits motility.  In collaboration with Dr. Tao’s laboratory, we performed mass 
spectrometry analyses and identified a number of proteins involved in 
cytoskeletal stability, particularly microtubule-associated proteins.  To assess 
how Syk modulates internal cytoskeletal networks and their influence on 
mechanical properties of breast cancer cells, we collaborated with Dr. Raman to 
utilize atomic force microscopy to capture Syk-dependent changes in the 
physical properties of breast cancer cells.  We discovered that Syk promotes 
microtubule stability when cells are treated with drugs that promote disassembly 
of microtubule polymers.  As a result, cells expressing Syk display a different 
physical phenotype compared to cells that lack Syk.  For example, Syk 
expressing cells are much stiffer and more elastic than are cells lacking Syk.  We 
identified MAP1B as one of the microtubule-stabilizing proteins through which 
Syk functions retain the microtubule architecture when cells are treated with 
depolymerizing agents.  It appears that MAP1B is needed to retain a less-
metastatic phenotype. 
 Our laboratory has recently identified a number of mRNA processing 
proteins from mass spectrometric analyses of Syk-binding proteins.  One of the 
binding proteins is G3BP, a critical component of stress granules.  We 
hypothesized that Syk could be recruited to stress granules and as a result 
modulate survival of breast cancer cells.   We discovered that Syk utilizes its 
linker B region, and is recruited to stress granules via an interaction with Grb7.  
At the stress granules, it promotes their clearance by autophagy in a manner 
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dependent on its catalytic activity and ability to bind stress granules.  
Consequently, Syk promotes the survival of breast cancer cells via enhanced 
autophagy in cells in which stress granules have been induced.  Together, our 
studies indicate that Syk influences many aspects of cellular biology and cancer 
biology via cytoskeletal networks and mRNA processing machinery, and this 
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CHAPTER 2. CALLING IN SYK: SYK'S DUAL ROLE AS A TUMOR PROMOTER 





 The autonomous growth of cancer cells is driven by an array of mutations, 
amplifications, rearrangements and modifications affecting hundreds of distinct 
genes. Only a limited number of these genes express proven, effectively 
druggable targets. Prominent among these are protein kinases, important 
components of the signal transduction machinery of eukaryotic cells that regulate 
the interactions of the cell with its environment and control such processes as 
energy metabolism, cell cycle progression, cytoskeletal rearrangement, gene 
expression and apoptosis. Tyrosine-protein kinases, which account for 17% of 
the human kinome, are particularly attractive drug targets due to their intimate 
involvement with the regulation of cell proliferation and survival and their frequent 
association with tumorigenesis.1,2 Thus, a number of therapeutic agents targeted 
against tyrosine kinases including imatinib (Gleevec) for the inhibition of BCR-
ABL, gefitinib (Iressa) and erlotinib (Tarceva) for targeting activated mutants of 
the epidermal growth factor receptor (EGFR) and trastuzumab (Herceptin) for the 
inhibition of human epidermal growth factor receptor-2 (HER2) are important 
components of the oncologist's armamentarium.1  While a role in malignant  
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transformation for many kinases is well documented, the ability of others to 
modulate the growth properties of cancer cells is less well understood. SYK 
(spleen tyrosine kinase) is a prime example since both tumor promoting and 
tumor suppressing roles for this enzyme have been described. 
 SYK was originally isolated by our group from bovine thymus and by the 
Yamamura group from porcine spleen.3-5 These tissue sources are consistent 
with expression analyses, which confirm that SYK is expressed at highest levels 
in cells of hematopoietic origins.6-8 SYK functions as an essential component of 
the signaling machinery of multiple receptors in the immune system that play 
important roles in distinguishing self from nonself.9 SYK contains a tandem pair 
of SH2 (Src homology 2) domains at the N-terminus that are separated from 
each other by a linker A region.10 A longer linker B region separates the SH2 
domains from the catalytic domain. Structural analyses indicate that hydrophobic 
residues in linker A, linker B and the catalytic domain interact to restrict SYK to a 
largely autoinhibited conformation.11 SYK is activated when it is recruited to an 
immune recognition receptor through the binding of its SH2 domains to a doubly 
phosphorylated immunoreceptor tyrosine-based activation motif or ITAM, a 
sequence of amino acids found on most SYK-coupled receptors.12 ITAMs consist 
of two sets of YXXL/I sequences separated by 6–10 amino acids. Examples of 
receptors possessing ITAM-containing components include the B cell receptor for 
antigen (BCR); receptors for IgE (Fc RI), IgG (Fc RIIa) and IgA (Fc RI), the 
collagen receptor of platelets (GPVI) as well as NK cell activating receptors and 
integrins that signal through associated DAP12 or FcR  components.    
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Following receptor engagement and clustering, a member of the Src-family of 
tyrosine kinases catalyzes the phosphorylation of the more N-terminal tyrosine 
within the ITAM to initiate the recruitment of SYK to the receptor.9-13 
Phosphorylation of the second ITAM tyrosine, likely by SYK, completes the 
formation of the receptor-SYK complex. Binding to dually phosphorylated ITAMs 
relieves autoinhibition to activate SYK, which then catalyzes the phosphorylation 
of protein substrates primarily on tyrosines located in sites rich with acidic amino 
acids (however, recent evidence has shown that SYK also has the ability to 
phosphorylate some proteins on serine).11,13-15 SYK itself has multiple tyrosines 
that become phosphorylated that regulate its activity and its ability to participate 
in protein–protein interactions.13 Substrates for SYK consist of 
adaptor/scaffolding proteins such as BLNK, SLP76 and LAT, and multiple 
regulatory enzymes that include lipid kinases, phospholipases and guanine 
nucleotide exchange factors.9,13  These phosphorylations serve to couple 
liganded receptors to the activation of signaling cascades that include the 
PI3K/AKT/mTOR, Ras/ERK, PLC /NFAT, and IKK/NF B pathways. These, in 
turn, are important modulators of metabolism and gene transcription that 
determine the physiological responses of an immune cell to receptor 
engagement. The critical involvement of SYK in the activation of immune cells 
has made it a popular target for anti-inflammatory therapeutics directed against 




 In addition to SYK's presence in most hematopoietic cells, there are 
multiple reports of SYK in various cell types outside of the immune system, 
particularly in epithelial cells from a variety of organs where it is present generally 
at much lower levels.6-8,17,18 For example, SYK is present in epithelial cells of the 
breast at levels at least 6-fold lower than in infiltrating immune cells.19  However, 
Syk haploinsufficient mice exhibit increased ductal outgrowth, suggesting an 
important role for SYK in tissue homeostasis in the breast.20 There also are many 
examples of individual cell lines that are not of hematopoietic origin that have 
levels of SYK mRNA as high as or even higher than those found in lymphoid cell 
lines.8 
 
2.2 SYK as a tumor promoter 
2.2.1. SYK and cell survival signaling downstream of the BCR in hematopoietic 
malignancies 
 Much of the attention on SYK as a promoter of cancer cell growth has 
focused on malignancies of B cell origins and the role of tonic or chronic 
signaling from the BCR in the maintenance of tumor cell viability. During the 
course of B cell development in the bone marrow, successful rearrangement of 
the immunoglobulin heavy chain locus yields a pre-B cell receptor that contains 
the heavy chain, surrogate light chains and an associated heterodimer of CD79a 
and CD79b, which are the signaling subunits that contain the ITAM sequences.21 
Successful gene rearrangement and receptor assembly are required for cells to 
survive the pro- to pre-B cell transition through signals sent from the pre-BCR via 
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SYK. Consequently, SYK-deficient B cell precursors largely fail to progress to the 
pre-B cell stage of development.22 Those that do make the transition, mainly 
through the expression of low levels of the SYK family kinase, ZAP-70, fail to 
progress further to become mature B cells.23 This latter transition requires 
rearrangement of the light chain locus and the production and expression at the 
cell surface of a mature B cell receptor, again associated with the CD79a and 
CD79b signaling components. At this stage of development, SYK is again 
required for cell survival and is thought to be activated by tonic signaling (i.e., 
signaling in the absence of antigen) from the assembled BCR complex.21 In fact, 
sustained BCR expression and tonic signaling are required for the continued 
survival of mature B cells.24 Signaling through the BAFF (B cell-activating factor) 
receptor, a tumor necrosis factor (TNF)-family receptor required for follicular B 
cell survival, also co-opts SYK, the BCR and its ITAMs as part of its mechanism 
to promote cell survival.25 
 In a mouse model of non-Hodgkin lymphoma, mice bearing both a c-Myc 
oncogene driven by an immunoglobulin enhancer (Eμ-MYC) and a HEL specific 
BCR (BCRHEL) develop lymphoid tumors that are reliant on tonic BCR signaling 
for survival.26  Further introduction of a soluble hen egg lysozyme transgene to 
generate an Eμ-MYC/BCRHEL/sHEL mouse results in the appearance of more 
aggressive tumors that are chronically activated through the BCR and resemble 




This supports the concept that either tonic or chronic signaling through the BCR 
contributes to tumorigenesis. In both tumor types, the silencing of SYK 
expression induces apoptosis and inhibits tumor formation in mice. 
 A prime example of a role for SYK and the BCR in tumorigenesis is B cell 
chronic lymphocytic leukemia (B-CLL). B-CLL arises due to the clonal expansion 
of phenotypically mature B cells. B-CLL cells are typically BCR positive and fall 
into two general classes: an indolent form with mutated immunoglobulin variable 
heavy chain region (IgVH) genes and a clinically aggressive form with unmutated 
IgVH genes that also express the SYK-family kinase, ZAP-70.27 ZAP-70 is not 
normally found in B cells and its ability to enhance tumorigenesis in B-CLL does 
not require it to be catalytically active, suggesting a scaffolding function for the 
enzyme.28 Cells of both classes are characterized by the presence of elevated 
levels of constitutively active SYK.29 Whether SYK activation occurs due to BCR 
engagement by an unknown antigen through chronic signaling—the IgM 
repertoire of B-CLL samples is less polymorphic than one would expect from 
random gene rearrangements—or from ligand-independent tonic signaling from 
the assembled BCR complex is not completely clear, although either mechanism 
may drive tumor development.30 
 The inhibition of SYK activity or the silencing of SYK expression in both 
indolent and aggressive B-CLL triggers apoptosis by the conventional 
mitochondrial/caspase 3 pathway.29,31,32  The highly malignant, unmutated class 
of cells is particularly dependent on the activity of SYK for survival.31 In a phase 
1/2 clinical trial of the SYK inhibitor fostamatinib, 55% of human patients with B-
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CLL had a positive response to therapy.33 Cells from treated patients exhibited a 
reduced profile of BCR-mediated activation events including decreased 
expression of NF- B and c-Myc target genes, reduced activation of BTK (a 
tyrosine kinase activated down stream of SYK), lowered levels of MYC and 
JUNB, and decreased expression of cell surface activation markers, all 
consistent with an inhibition of BCR signaling.34 
 BCR-dependent signaling also is involved in diffuse large B cell lymphoma 
(DLBCL). DLBCL is a heterogeneous collection of malignancies, a subset of 
which are BCR positive, display gene expression signatures consistent with anti-
IgM-activated B cells and are reliant for survival on the expression of 
components of the BCR complex.35 Many DLBCL cell lines exhibit tonic or 
chronic signaling from the BCR that results in the constitutive phosphorylation of 
SYK on activation loop tyrosines.36 An evaluation of 61 DLBCL tumor samples 
from human patients found that 44% had elevated levels of phosphorylated SYK; 
and this phosphorylated SYK was localized to the plasma membrane where BCR 
complexes are found.37 A fraction of primary DLBCL samples exhibit increases in 
SYK gene copy number, which correlates with increased protein expression. 
BCR-dependent DLBCL cells also frequently overexpress the transcriptional 
repressor, BCL6, which down regulates the expression of PTPROt, a receptor-
type protein tyrosine phosphatase and negative regulator of SYK-dependent 
BCR signaling.39 Thus, a decrease in PTPROt expression enhances tonic 
signaling from the BCR.40 The SYK inhibitors R406 and PRT318 are cytotoxic or 
cytostatic for most BCR-positive DLBCL cells.36,37 The knockdown of SYK by 
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siRNA arrests cell cycle progression in PRT318- sensitive DLBCL cell lines, 
which phenocopies the effects of the SYK inhibitor.37 Consistent with these 
observations, a positive response rate of 22% for DLBCL patients was observed 
in a clinical trial of fostamatinib.33 
 The constitutive activation of SYK also has been reported in other B cell-
derived malignancies including follicular lymphoma (FL), mantle cell lymphoma 
(MCL) and marginal zone lymphoma (MZL).41-43 Primary FL cells are 
hyperresponsive to BCR engagement as compared to tumor-infiltrating, but 
nonmalignant B cells.44 In MCL, a rare but deadly form of non-Hodgkin 
lymphoma, SYK is frequently overexpressed due to gene amplifications in both 
cell lines and primary tumor samples.42 In splenic MZL, SYK expression also is 
upregulated, potentially due to the downregulation of miR-27b and miR-377 
microRNAs, which are predicted to modulate SYK gene transcription.43,45 In both 
FL and MCL, the SYK inhibitor, piceatannol, is toxic to cells expressing 
constitutively active, phosphorylated SYK. In summary, the accumulating 
evidence indicates that SYK is clearly an important mediator of tonic and chronic 
signaling through the BCR in multiple B cell-derived lymphomas where it plays a 







2.2.2 SYK and cell survival signaling downstream of receptors other than the 
BCR in hematopoietic malignancies 
 A role for SYK in supporting tumor cell growth is not restricted to cells 
expressing ITAM-containing components of the BCR complex. In B cell acute 
lymphocytic leukemia (B-ALL) a large percentage of malignant cells are derived 
from pro-B cells that lack pre-BCR or BCR complexes. However, these tumor 
cells survive and develop many characteristics of pre-B cells even in the absence 
of the pre-BCR.46 Interestingly, most B-ALL cells and primary isolates from 
patients still have elevated levels of constitutively active, phosphorylated SYK 
and their growth both in culture and in tumor xenografts is attenuated by 
inhibitors of SYK activity.46-48 The expression of SYK can be detected in 94% of 
peripheral T cell lymphomas (PTCLs) and immunoblotting experiments indicate 
that the kinase is constitutively phosphorylated in these cells.49 The signals that 
act upstream of SYK to enhance its activity in B-ALL and PTCL remain to be 
identified, although the T cell antigen receptor (TCR) is a clear suspect in 
PTCL.50 
 In some lymphoid cancers, ITAM-containing proteins other than 
components of the BCR-signaling complex support the activation of SYK to 
promote cancer cell survival. During the latent stage of infection, Epstein–Barr 
virus (EBV) expresses the integral membrane protein LMP2A.51 LMP2A interacts 
with both Lyn and SYK, the latter through an N-terminal ITAM that, when 
phosphorylated, stably associates with SYK's tandem pair of SH2 domains. 
These interactions inhibit signaling through the BCR and prevent lytic replication. 
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Interestingly, LMP2A serves as a surrogate BCR to promote B cell differentiation 
even in the absence of cell surface immunoglobulins by providing the tonic 
signals required for B cell survival.52 Thus, B cells expressingLMP2A can 
populate lymphoid organs even in Rag-1-deficient mice. While EBV infections are 
nearly universal in adults, these are effectively controlled by a cytotoxic T cell 
response. However, EBV infections uncontrolled by adaptive immune responses 
in immunocompromised individuals can result in EBV+ post-transplant 
lymphoproliferative disorder (PTLD). The resulting mainly B cell-derived 
lymphomas are characterized by the appearance of constitutively active SYK.53 
Most are dependent on SYK expression and activity for survival as both siRNAs 
directed against SYK mRNA and the SYK inhibitor R406 induce apoptosis in 
these cells. 
 In acute myeloid leukemia (AML), integrins can function upstream of SYK 
to enhance its activity and support tumor cell growth. AML arises from the 
enhanced proliferation and defective differentiation of progenitor cells of the 
myeloid lineage and thus does not typically express components of the BCR 
complex. An investigation of the sensitivity of AML cells to inhibitors of EGFR 
(which is not expressed in AML), coupled with a siRNA screen, identified SYK as 
a key player in AML pathogenesis.54 Both siRNAs and inhibitors targeting SYK 
decrease proliferation and induce differentiation of AML cell lines and primary 
AML blasts and inhibit the growth of AML xenografts in mice.54 One clue to the 
upstream activator of SYK in AML came from a shRNA-based screen that 
identified 3-integrin (ITGB3) as an important factor supporting the proliferation 
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and inhibiting the differentiation of AML.55 Downregulation of ITGB3 expression 
by RNA interference decreases the level of phosphorylated and activated SYK 
and mimics the effects of SYK inhibitors on AML proliferation and differentiation. 
Another clue came from a mass spectrometric-based analysis of SYK interacting 
proteins in AML cells that identified Mac-2 ( 2 Mintegrin) and Fc RI as key SYK-
binding partners.56 The engagement of either receptor is coupled to the activation 
of SYK. Interestingly, the knockdown of CD18 ( 2-integrin) or of the FcR  chain 
attenuates the SYK dependent proliferation of AML cell lines. In both neutrophils 
and macrophages, the integrin-mediated activation of SYK requires the 
expression of either DAP12 or FcR  (FCER1G), both of which contain ITAM 
sequences that, when phosphorylated, associate with SYK. The constitutive 
phosphorylation of the FcR  ITAM and its association with SYK were observed in 
AML cells, suggesting its role in the tonic activation of SYK.56,57 
 Approximately 1/3 of patients with AML have mutations in the FLT3 gene 
that result in the expression of a constitutively active receptor tyrosine kinase. In 
these cells, a role for SYK also has been implicated.58 Active, phosphorylated 
FLT3 physically associates with SYK through its more C-terminal SH2 domain 
and SYK, in turn, enhances the activity of FLT3 by phosphorylation. This 
cooperative activation of both kinases leads to an increase in the expression of 





2.2.3 SYK fusion proteins in hematopoietic malignancies 
 An alternative way to generate tonic, SYK-dependent signals is through 
gene rearrangements and the production of constitutively active fusion proteins. 
Data generated from next generation sequencing indicates that SYK is rarely 
mutated in any type of cancer.59 Thus, point mutations in SYK do not appear to 
be important drivers of tumorigenesis. However, chromosomal translocations 
involving the SYK gene have been detected and these can result in the 
production of fusion proteins that promote myeloproliferative or 
lymphoproliferative diseases. For example, a fusion protein in which the 
dimerization domain of the TEL gene product is fused to SYK results in an active 
kinase that promotes a myeloproliferative disorder.60 Constitutive activation 
requires the TEL oligomerization domain and results in the phosphorylation on 
tyrosine of the fusion protein. The oligomerization of TEL-SYK through the TEL 
domain likely mimics the activation of SYK that occurs during the clustering of the 
receptors with it associates. This stimulates SYK autophosphorylation on sites 
that modulate its activity and promote its interactions with downstream effectors 
that bear SH2 or functionally related domains.13 
 A fusion protein that contains the N-terminal Tec and PH homology 
domains of the tyrosine kinase ITK fused to most of linker B and the catalytic 
domain of SYK is found frequently in nonspecific PTCLs. The resulting fusion 
protein is constitutively active and its expression leads to the phosphorylation of 
downstream adaptor and effector proteins.61,62 Unlike TEL-SYK, ITK-SYK 
expression selectively leads to T cell lymphoproliferative diseases, perhaps due 
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to a requirement for the expression of SLP-76, which is critical for ITK-SYK 
activation and the subsequent phosphorylation of either SYK or ZAP-70, which 
then play important adaptor functions downstream of activated TEL-SYK perhaps 
similar to the role played by ZAP-70 in B-CLL.63 Expression of neither the TEL-
SYK nor ITK-SYK fusion protein alone is likely to be sufficient for full B or T cell 
transformation as recent mouse models indicate that additional genetic changes 
are required to overcome SYK induced, Blimp-1-mediated terminal 
differentiation.64 
 
2.2.4 SYK and ITAM-signaling in non-hematopoietic malignancies 
 The inappropriate activation of SYK through the abnormal expression of 
ITAM-containing proteins can contribute to cell transformation in non-
hematopoietic cells. For example, mouse mammary tumor virus (MMTV), which 
causes adenocarcinomas in mice, expresses an env gene product that, when 
expressed in mammary epithelial cells, induces morphological changes 
consistent with transformation.66 The Env protein contains an ITAM sequence 
through which it associates with SYK. Env-induced transformation requires the 
conventional pair of ITAM tyrosines and is blocked by the SYK inhibitor, 
piceatannol. Similarly, the ITAM of LMP2A, which contributes to cancer cell 
survival in PTLD, also influences the physical properties of EBV-induced 
nasopharyngeal carcinoma cells.67 LMP2A associates with SYK via its ITAM and 
enhances motility in a manner dependent on the conserved ITAM tyrosines and 
on the expression and activity of SYK. The ectopic expression of LMP2A in 
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keratinocytes also promotes cell migration in an ITAM- and SYK-dependent 
manner by inducing the translocation of V-integrin to the membrane.68 The gene 
for C35 (C17orf37), which is located on the HER2 amplicon, is increased in 
expression with HER2 gene amplification in human breast cancer.69 C35 also 
has an ITAM and its expression in mammary epithelial cells induces invasive 
growth and triggers an epithelial-to-mesenchymal transition (EMT) as 
characterized by a loss of E-cadherin. This activity requires both the C35 ITAM 
sequence and SYK. It is interesting that, in many of these same cell types, the 
expression of SYK in the absence of ITAM containing effectors like Env, LMP2A 
and C35 actually inhibits cell motility and EMT (see below). Thus, these 
aberrantly expressed, ITAM containing molecules may sequester SYK away from 
its normal interacting partners within the cell in much the same way that LMP2A 
expression inhibits BCR signaling in EBV+ B cells. They potentially could localize 
active SYK near a particular set of substrates whose phosphorylation alters 
cellular growth properties. 
 
2.2.5 SYK and cell survival signaling in non-hematopoietic malignancies 
 Oncogenic mutations in K-Ras are seen frequently in adenocarcinomas of 
the pancreas, lung and colon. A recent analysis compared gene expression 
profiles of lung and pancreatic cancer cells dependent on the expression of 
oncogenic K-Ras for survival to tumor cells not dependent on K-Ras.70 
Interestingly, SYK is the gene most commonly expressed in K-Ras-dependent (or 
K-Ras addicted) cells that is missing from K-Ras-independent cells. Accordingly, 
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SYK protein levels are relatively high in K-Ras addicted cells. In these cells, the 
knockdown of SYK expression or inhibition of SYK activity results in caspase 3 
activation and cell death. The expression in many cells of oncogenes like K-Ras 
induces apoptosis unless cells acquire additional anti-apoptotic measures.71 
Thus, it is likely that the pro-survival activity of SYK protects these cells from K-
Ras-induced apoptosis. 
 A similar pro-survival role for SYK is seen in retinoblastoma.72 Whole 
genome sequencing of retinoblastoma cells reveals no significant mutations in 
any oncogenes or tumor suppressor genes other than RB1. However, many 
epigenetic changes in gene methylation are observed, including reduced 
methylation of the SYK gene promoter. As a consequence, SYK is expressed in 
both retinoblastoma orthotopic xenografts and cell lines, but is actually absent 
from normal retina. Both the application of SYK inhibitors and knockdown of SYK 
expression by shRNA result in a dramatic increase in mitochondrial-based 
apoptosis. The addition of a SYK inhibitor to the chemotherapeutic regimen used 
to treat retinoblastoma in a mouse model significantly improves outcomes, clearly 
suggesting SYK as a promising therapeutic target for the treatment of childhood 
retinoblastoma.72 Thus, the expression of SYK can protect cancer cells from the 






 For many tissues—including brain, colon, kidney and ovary—the levels of 
SYK mRNA are, in general, higher in cancerous than in normal tissues, 
suggesting possible roles for the kinase in tumorigenesis in many cell types 
outside of the immune system.8 In ovarian cancer, for example, the expression 
level of SYK increases with tumor grade.73 Tumors of low malignant potential 
have lower levels of SYK, intermediate levels are present in grade 1 tumors, and 
the highest levels are found in aggressive grade 3 cancer cells. The silencing of 
SYK expression markedly inhibits anchorage-independent growth and induces 
apoptosis in SYK-expressing ovarian cancer cells. An analysis of genes co-
expressed in small cell lung cancer (SCLC) reveals SYK as a potential oncogenic 
driver.74 An examination of primary tumor samples found SYK present in 11 of 33 
SCLC tissues at levels much higher than those in normal alveolar epithelium. 
Also, a large majority of SCLC cell lines overexpress SYK mRNA.75 The silencing 
of SYK expression by siRNA decreases cell growth and increases apoptosis in 
SYK-positive SCLC cells. Similarly, SYK is frequently found in squamous cell 
carcinomas of the head and neck (SCCHN) where its expression enhances cell 
migration.76 Interestingly, elevated SYK expression is also observed in SCCHN 
patient tissues where it correlates with increased metastases to the lymph nodes 






2.2.6 Mechanisms of SYK-dependent survival signaling 
 A fundamental hallmark of a cancer cell is its ability to resist apoptosis, a 
capability enhanced by the expression of Syk (Figure 2.1).77 Signaling through 
PI3K and AKT, known mediators of pro-survival signaling, is thought to underlie 
SYK's role as a promoter of tumorigenesis in many tumors. In normal B cells, 
SYK couples the antigen receptor to the activation of the PI3K/AKT pathway.78,79 
The activation of PI3K generates phosphatidylinositol 3,4,5-trisphosphate (PIP3), 
a membrane anchor for and activator of the serine/threonine kinase, AKT. 
Activation of PI3K and AKT in response to BCR-signaling is essential for the 
BCR and SYK-dependent tonic signaling that promotes cell survival in normal B 
cells as the death of mature B cells resulting from the induced deletion of the 
BCR can be rescued by expression of a constitutively active form of PI3K or by 
deletion of PTEN.80 
 AKT is a pleiotropic kinase that controls survival signaling through the 
phosphorylation of multiple downstream substrates that play key roles in 
regulating the activity and/or expression of pro- and/or antiapoptotic proteins. 
Multiple mechanisms are operative in different tumor cell types. An important 
downstream target of pro-survival signaling in B-CLL is MCL-1, an anti-apoptotic 
member of the Bcl-2 family of cell death regulatory proteins.81 The silencing 
ofMCL-1 by RNA interference leads to cell death, indicating its importance as a 
downstream target of survival pathways.82 B-CLL cells in general exhibit a SYK 
dependent increase in the basal state of phosphorylation of AKT. Activated AKT 
phosphorylates and inhibits glycogen synthase kinase 3 (GSK3), a negative  
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regulator of MCL-1 protein stability. GSK3 targets MCL-1 for destruction by 
phosphorylating it on Ser-159, which stimulates its ubiquitination by the Fbw7-
containing Skp1-Cullin-F-box complex (SCF) to trigger subsequent proteasomal 
degradation.83 Interestingly, PKC  also is a downstream target of activated SYK 
in B-CLL cells.29 Active PKC  promotes the activation of AKT and also functions 
independently of AKT to inactivate GSK3 and stabilize MCL-1. This provides an 
alternative mechanism by which the level of MCL-1 can be regulated even in 
subsets of B-CLL cells in which AKT is not demonstrably activated. Thus, the 
treatment of cells with inhibitors of SYK results in the downregulation of MCL-1 at 
the level of protein stability due to an AKT and/or PKC -mediated inhibition of 
GSK3. In retinoblastoma, the expression of SYK also protects MCL-1 from 
degradation, indicating that this mechanism is likely to be operative in multiple 
tumor types.72  
 Activation of the PI3K/AKT pathway also is an important promoter of cell 
survival in DLBCLs, although the consequences of activation vary with tumor 
type. In BCR-dependent DLBCLs exhibiting high levels of activated NF- B, the 
inhibition of SYK or PI3K attenuates the transcription of NF- B-regulated genes 
that include BCL2A1, a gene that codes for an anti-apoptotic member of the 
BCL-2 family.38 In contrast, in BCR dependent cells with low levels of NF- B, 
BCR signaling represses the expression of HRK, a BH3 domain-only pro-
apoptotic protein.38 Inhibitors of either SYK or PI3K enhance the expression of 
HRK, which then promotes apoptosis through its interactions with anti-apoptotic 
proteins such as BCL-2 and Bcl-xL.38,84 
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 The expression of LMP2A in EBV-infected cells promotes cell survival 
through the SYK-dependent, constitutive activation of PI3K/AKT, which enhances 
the expression of the anti-apoptotic protein, BCL-XL (BCL2L1), and protects 
EBV+ Burkitt's lymphoma cells from MYC-induced apoptosis.85,86 In EBV+B cell 
lymphomas, the inhibition of SYK also results in the degradation of the caspase 3 
inhibitor, XIAP, due to a decrease in the AKT-dependent inhibition of HTRA2, a 
protease for which XIAP is a known substrate.52,87 
 Mammalian target of rapamycin (mTOR) is a serine/threonine kinase and 
well known regulator of tumor growth and proliferation that is activated 
downstream of the PI3K/AKT pathway.88 In AML, inhibitors or shRNA targeting 
SYK suppress the activity of mTOR, which is constitutively active in untreated 
cells.89 Combinations of SYK inhibitors with inhibitors of PI3K or mTOR synergize 
to induce AML cell differentiation. 
 Interesting positive feed-forward signals also can be stimulated through 
the PI3K/AKT pathway to enhance the efficiency of BCR signaling in some tumor 
cells. The BCR-mediated activation of SYK and PI3K/AKT in DLBCLs activates 
the transcription factor SREBP, a key regulator of genes required for cholesterol 
biosynthesis.38 The resulting increased expression of enzymes of the cholesterol 
anabolic pathway elevates plasma membrane cholesterol, which enhances BCR-
signaling by promoting receptor clustering within cholesterol rich membrane 
microdomains or lipid rafts. Additionally, the SYK-dependent activation of AKT 
and consequent inhibition of GSK3 increase the intracellular level of MYC, whose 
degradation is enhanced when phosphorylated by GSK3. MYC activates the 
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miR17-92 cluster of microRNAs, which enhance BCR signaling by 
downregulating the expression of inhibitory proteins including CD22 and Fc RIIb 
(FCGR2B).90 Both CD22 and Fc RIIb contain within their cytoplasmic tails 
immunoreceptor tyrosine-based inhibitory motifs (ITIMs). ITIMs, when 
phosphorylated on tyrosine, bind negative regulators of BCR signaling including 
the lipid phosphatase SHIP1 and the tyrosine phosphatase SHP-1.91 Thus, either 
enhanced expression of MYC or of the miR17-92 cluster reduces the expression 
of ITIM-containing proteins to promote the BCR-dependent activation of 
downstream signaling effectors that include SYK, PI3K and AKT. 
 SYK also is tied to pro-survival pathways not directly associated with 
increased activity of the PI3K/AKT pathway. In multiple cell types including 
DLBCL, Burkitt's lymphoma, and breast carcinoma, an interaction of SYK with 
nucleolin (NCL) promotes the binding to NCL of the mRNA coding for the anti-
apoptotic protein, BCL-XL, but not the alternatively spliced message coding for 
the smaller pro-apoptotic protein, BCL-XS.92 This interaction with NCL stabilizes 
the BCL-XL transcript from being degraded in response to oxidative or genotoxic 
stress. SYK also influences the activity of signal transducer and activator of 
transcription (STAT) proteins, transcription factors that are activated through 
phosphorylation on tyrosine. Of the many STAT proteins, STAT3 and STAT5 in 
particular are key regulators of tumor cell survival.93 Proteomic analyses of SYK-
interacting proteins in AML identified both STAT3 and STAT5 as direct binding 
partners of SYK.56 Both are constitutively activated and phosphorylated in AML 
cells in which tonic signaling and SYK activation are mediated by integrins and 
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FcR . The expression of constitutively active forms of STAT3 or STAT5 rescues 
AML cells from the anti-proliferative effects of inhibitors of SYK activity or 
expression. Similarly, the expression in cells of the TEL-SYK fusion protein 
results in the phosphorylation of STAT5, while STAT3 is phosphorylated in both 
B-CLL and B-ALL cells through a SYK dependent pathway.31,94,95 Interestingly, 
the activation of STATs occurs via pathways independent of Janus kinases 
(JAKs), the canonical upstream regulators of STAT activity. Finally, in ovarian 
cancer cells, SYK promotes cell survival by inhibiting the expression of C-JUN.  
Consequently, apoptosis triggered by a loss of SYK is partially rescued by 
inhibitors of JNK, the upstream activator of C-JUN.73 
 
2.3 SYK as a tumor suppressor 
2.3.1 SYK and tumor suppression in B-ALL 
 The vast bulk of the evidence from studies on tumor cells of hematopoietic 
origins indicates that the presence of SYK and its activation are important for cell 
survival and, as such, promotion of tumor growth with one notable exception. The 
abnormal alternative processing of SYK mRNA leads to a dramatic reduction in 
SYK expression and activity in childhood CD19+CD10- pro-B cell ALL that likely 
arrests cellular maturation at the pro-B cell to pre-pre-B cell transition. This is a 





2.3.2 SYK and tumor suppression in carcinomas 
 Defining a precise role for SYK in carcinomas, cancers derived from 
epithelial cells, has been a complicated process. In some cell and tissue types, 
SYK appears to be associated with a malignant phenotype as discussed above. 
However, for many tumor types, SYK is encountered frequently in well or 
moderately differentiated carcinomas, but it is absent from poorly differentiated 
and invasive cells. Its knockdown in more well differentiated cancers enhances 
invasive growth behaviors while its re-expression in highly malignant cancer cells 
retards motility and inhibits metastasis. Thus, SYK is frequently described as a 
tumor suppressor in many epithelial cell-derived cancers. 
 An inverse relationship between SYK expression and tumor progression 
was first described by Mueller and co-workers studying a role for the kinase in 
mammary carcinogenesis.97 At both the mRNA and protein levels, SYK is 
present in normal mammary gland epithelial cells and in breast cancer cells of 
low metastatic potential, but is absent from highly invasive, malignant cell lines. 
In patient samples, the loss of SYK during tumor development is progressive with 
levels of the kinase reduced in ductal carcinoma in situ (DCIS) and lost in 
invasive breast cancer.19.98 Distant metastases are more frequently encountered 
in breast cancer patients with reduced levels of SYK mRNA.99 The loss of SYK is 
a consequence of both the methylation of CpG islands in the SYK promoter and 
allelic loss. The SYK promoter is frequently hypermethylated in primary breast 
tumors, but unmethylated in adjacent normal breast tissue.100  Heterozygotic loss 
of the SYK gene is frequent in invasive ductal carcinoma (IDC) and in DCIS 
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located adjacent to IDC. Consequently, Syk haploinsufficient mice exhibit an 
increased risk of mammary tumors.20 
 A similar asymmetric distribution of SYK between well and poorly 
differentiated cancer cells is seen in a number of different tumor tissues. SYK is 
present in normal ducts and ductules in the pancreas and in well differentiated 
malignant ducts, but is lost as pancreatic ductal adenocarcinoma (PDAC) cells 
progress through moderately differentiated to poorly differentiated.101 Similarly, 
SYK is present in differentiated PDAC cell lines, but is absent from less 
differentiated lines. Interestingly, the pancreatic and lung cancer cells dependent 
on K-RAS (and SYK) for survival have a more epithelial morphology while K-
RAS-independent cells that lack SYK have a mesenchymal morphology.70 
Decreases in the expression of SYK in more malignant, invasive tumor cells due 
to epigenetic silencing are also seen in bladder cancer, colorectal cancer, 
melanoma, gastric cancer, nasopharyngeal cancer, and hepatocellular 
carcinoma (HCC).102-109 Interestingly, SYK levels are controlled also at the 
protein level by CHK1, which is frequently overexpressed in HCC. CHK1 
phosphorylates SYK on Ser-295 promoting its ubiquitination and proteasomal 
degradation.110 
 Carcinomas at the primary tumor site generally have an epithelial 
morphology, are tightly packed, and are characterized by the expression of E-
cadherin located at the sites of fixed cell–cell junctions. The process by which 
cancer cells leave the primary tumor to enter the circulation and travel to distant 
sites requires a transition to a mesenchymal phenotype characterized by a loss 
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of cell polarity, increased motility, and enhanced invasive properties.111 This 
epithelial-to-mesenchymal transition (EMT) is crucial for embryogenesis and 
organ development, but cancer cells use this process to initiate invasion and 
metastasis. Variances in the expression of SYK in poorly versus well or 
moderately differentiated tumor cells likely reflect intrinsic effects of the kinase on 
the differentiation and physical properties of these cells that include the 
regulation of EMT. The expression in immortalized, but nontransformed, 
MCF10A breast epithelial cells of a shRNA targeting SYK increases cell motility, 
invasion, and growth in soft agar and induces a more fibroblast-like morphology 
characteristic of EMT.20 Analysis of changes in gene expression resulting from 
the silencing of SYK expression confirms the loss of epithelial gene products and 
the increased expression of genes characteristic of mesenchymal cells. Similarly, 
a catalytically inactive form of SYK expressed in MCF7 cells acts as a dominant 
negative mutant to increase tumorigenesis in a mouse xenografts model.97 
Comparable results are observed in K-Ras addicted pancreatic carcinomas 
where the knockdown of SYK expression leads to a loss of E-cadherin 
expression, a characteristic feature of EMT.70 Interestingly, SYK is included in the 
EMT core gene signature as a gene reduced in expression in breast cancer cells 
undergoing EMT in response to multiple EMT-inducing transcription factors.112 
Thus, SYK is a negative regulator of the EMT process, which likely explains 
much of its differential expression in well versus poorly differentiated tumors. 
 The ability of SYK to enhance and support the growth properties of cells 
with an epithelial phenotype likely underlies its growth inhibitory effects when re-
61 
expressed in more malignant, invasive mesenchymal cells that normally lack 
SYK. The re-introduction of SYK into highly invasive breast carcinomas reduces 
cell motility, invasive growth and slows tumor growth and inhibits metastases in 
animal xenograft models.97,113 Similar reductions in cell migration and invasion 
are seen when SYK is re-expressed in SYK-negative hepatocellular carcinoma, 
colorectal cancer, melanoma and pancreatic adenocarcinoma.101,103-105,109 Gene 
expression analyses of SYK-negative Panc1 cells identified significant changes 
in the expression of over 2000 genes resulting from the re-expression of SYK 
including genes such as MMP2 that are required for invasive growth. Panc1 cells 
in which SYK is re-expressed develop a more differentiated phenotype and have 
increased cell–cell interactions, which is consistent with the ability of SYK to 
enhance cell–cell interactions in breast cancer cells.101,113 Rapid changes in the 
physical properties of cancer cells expressing SYK can be observed upon the 
application of inhibitors of the kinase.113 Thus, the negative effect of SYK on the 
growth properties of metastatic tumor cells is likely a product both of SYK-
dependent changes in gene expression and the more direct effects of 
phosphorylation of modifiers of cytoskeletal dynamics.114,115 For example, SYK 
can catalyze the phosphorylation of cytoskeletal proteins such as -tubulin, 
cortactin, E-cadherin, -catenin and MAP1B.113-117 SYK also is recruited to the 
centrosome where multiple substrates are located.118,119 It is this ability of SYK to 
enhance adhesion and negatively affect motility and invasion that explains its 
absence from highly aggressive tumor cells and underlies its classification as a 
tumor suppressor in certain tumor cell types. 
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 As carcinoma cells progress to a more highly invasive phenotype, the 
suppression of SYK expression and activity likely requires the upregulation of 
additional mechanisms for survival. For example, many K-Ras independent 
carcinomas are deficient in PTEN and have high levels of active AKT, which 
promotes cell survival. Interestingly, a fraction of primary DLBCL samples exhibit 
increases in the SYK gene copy number while a distinct subset exhibits a loss of 
PTEN, suggesting that both mechanisms may independently promote cell 
survival.38,70 
 
2.3.3 Alternative splicing of SYK 
 Transcription of the SYK gene gives rise to two alternatively spliced 
products: full-length SYK, which is sometimes referred to as Syk(L), and the 
shorter gene product SYKB, also referred to as Syk(S). SYKB lacks a stretch of 
23 amino acids in linker B, referred to as the linker insert or DEL, and is 
intrinsically less active as compared to SYK in coupling the BCR to intracellular 
signaling.120,121 Growing evidence indicates that SYK and SYKB have different 
effects on the growth properties of cancer cells. SYKB is found, along with SYK, 
in many breast cancer cell lines in which the SYK gene is not silenced, but is 
missing from normal breast epithelial cells.120 Interestingly, unlike full-length SYK, 
the ectopic expression of SYKB in highly invasive breast cancer cells fails to 
reduce cell invasiveness.120 Similarly, the expression pattern of SYK versus 
SYKB varies in HCC. SYK levels are down-regulated in HCC tumor samples as 
compared to normal liver tissue, but SYKB levels are actually higher in HCC.122 
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Since the phosphorylation site on SYK for CHK1 is located in the DEL sequence, 
elevated levels of CHK1 also lead to the selective loss of the full-length kinase 
while not affecting the level of SYKB.110 The re-expression of SYK, but not SYKB 
in SYK negative HCC cells inhibits cell growth in vitro and tumor growth and 
metastasis in vivo.122 In fact, the expression of SYKB moderately enhances 
tumor cell growth and promotes the formation of lung metastases in mice. Of the 
two splice isoforms, SYKB is found preferentially in poorly differentiated HCC 
cells where its presence correlates with increased features of cells having 
undergone EMT. In fact, the expression of SYKB is a significant indicator of poor 
prognosis in HCC patients.122 Thus, SYKB lacks the tumor suppressive activities 
of SYK, and its expression may actually contribute to a more highly transformed 
phenotype. 
 Even in cells where the overall effect of the elevated expression of SYK 
enhances tumorigenesis, differences exist in the properties of the two splice 
isoforms. An analysis of alternative splicing and its contributions to tumor cell 
survival identified splicing of the SYK transcript as a major contributor to ovarian 
cancer cell survival.73 In this system, the induction of SYK promotes cell survival, 
while the manipulation of SYK gene splicing to decrease SYK and increase 
SYKB induces apoptosis. While the level of expression of SYK selectively 
reduces the expression of C-JUN to inhibit apoptosis, SYK-dependent changes 
in anchorage-independent growth are more a product of the total level of SYK 
isoforms expressed. Interestingly, the treatment of cells with EGF selectively 
promotes the expression of the full-length kinase to promote cell survival. 
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 The differential effects of SYK and SYKB on the properties of cancer cells 
are generally attributed to differences in their respective localizations within the 
cell. Cellular fractionation and immunofluorescence studies indicate that SYK is 
present in both the nucleus and cytoplasm, but SYKB is confined to the 
cytoplasm.73,120,122 SYK, but not SYKB, can enter the nucleus where it interacts 
with histone deacetylases and the transcription factor Sp1 to repress the 
transcription of Sp1 regulated oncogenes such as CCD1 (cyclin D1) and FRA1 
(FOSL1). Consistent with such a mechanism, the appearance of SYK in the 
nucleus is of positive prognostic significance in gastric cancer.107 
 The basis of the differential localization of SYK and SYKB is not entirely 
clear. The DEL region resembles a bipartite nuclear localization signal (NLS) and 
the replacement of basic amino acids within this sequence results in the 
exclusion of SYK from the nucleus.120 However, the replacement of Y290 (based 
on the murine Syk numbering system) with a phenylalanine has the same effect, 
but this change actually converts the DEL into a nuclear export sequence 
(NES).124 Attachment of the entire linker B region, but not the DEL sequence, to 
a heterologous protein can deliver it into the nucleus.120 However, this activity 
maps to a region located near the C-terminal end of the linker, well removed from 
the DEL, which is located in the N-terminal one-third of linker B.124 The 
localization of full-length SYK itself also is subject to regulation as integrin 
clustering, BCR engagement and PKC activation result in a translocation of SYK 
out of the nucleus.113,124 Regardless of the mechanism, it is clear that an analysis 
of changes in the levels of total SYK plus SYKB mRNA and/or total SYK plus 
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SYKB protein (e.g., as measured by immunofluorescence microscopy) can be 
misleading when assessing the potential involvement of SYK in modulating the 
growth properties of a particular cancer type. 
 
2.4 Conclusions 
 The ability of SYK to function as either a promoter (Table 2.1) or 
suppressor (Table 2.2) of malignant cell growth appears to be highly dependent 
on the cell type and its stage of differentiation, the relative levels of the two SYK 
isoforms that are expressed, the mechanisms acting upstream of the kinase that 
lead to its activation, and the biological role played by the kinase. The expression 
of SYK in cancer cells affects their growth properties primarily through three 
mechanisms: 1) The presence of SYK promotes cell survival by stabilizing at 
both the protein and mRNA level the expression of anti-apoptotic proteins. This 
activity underlies many of the tumor promoting activities of the kinase. 2) The 
presence of SYK alters gene expression to affect cellular differentiation programs 
that regulate EMT. This requires that SYK has the capacity to transit from the 
cytoplasm into the nucleus. This activity likely explains the differential expression 
of SYK between cancer cells of epithelial versus mesenchymal phenotypes. 3) 
As a consequence of its catalytic activity, the presence of SYK alters cytoskeletal 
dynamics to affect cell–cell and cell–matrix adhesion and cell motility. This 
activity likely underlies many of the tumor suppressive activities of the kinase 
when reexpressed in mesenchymal cells. However, the latter two functions of 
SYK can be corrupted by the elevated or abnormal expression of molecules 
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bearing ITAM sequences that result in the aberrant sequestration and 
relocalization of the kinase. This dual role for SYK is likely to be a complicating 
factor in the development of SYK inhibitors for therapeutic purposes as it will be 






















Table 2.1 Cancers in which SYK functions as a tumor promoter. 
Cancer Type Observation Reference 
B-cell lymphocytic 
leukemia (B-CLL)  
Constitutively active SYK 28,31,32 
Diffuse large B-cell 
lymphoma (DLBCL) 





SYK inhibition induces 
apoptosis 
41 
Mantle cell lymphoma Inhibition induces 
apoptosis  
42 
Peripheral T cell 
lymphoma 
Constitutively active SYK 49,62 
Lung cancer K-Ras dependent cells 68 
Retinoblastoma Inhibition induces 
apoptosis 
70 
Ovarian cancer Inhibition induces 
apoptosis 
71 




carcinoma of the head 
and neck 




Table 2.2 Cancers in which SYK functions as a tumor suppressor. 
Cancer Type Observation Reference 
Childhood CD19+CD10- 
pro-B-ALL  
SYK loss leads to 
malignancy 
94 
Breast cancer Decreased SYK 
expression correlates 
with invasion, metastasis, 




Loss of SYK in less 
differentiated tumor cells 
68,69 
Bladder cancer Decreased expression  100 
Colorectal cancer Decreased expression 101 
Melanoma Epigenetic silencing 103 
Gastric cancer Decreased expression 104,105 
Nasopharyngeal cancer Decreased expression 106 
Hepatocellular 
carcinoma 
Decreased expression 107 
Ovarian cancer SYK promotes cell 
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3.1 Plasmids and DNA constructs 
 Constructs expressing the following EGFP fusion proteins: wild-type (Syk-
EGFP), kinase dead Syk (Syk-EGFP(K396R)), Syk single-site mutants (Syk-
EGFP(Y342F) and Syk-EGFP(Y346F)), Syk double-site mutant (Syk-
EGFP(Y342F/Y346F)), and analog-sensitive Syk (Syk-
EGFP(R428Q/M429L/M442A), also referred to as Syk-AQL-EGFP) were 
generated in the EGFP-N2 vector as previously described (insert reference).  
The corresponding cDNAs were amplified by PCR and cloned into the pCDH-
CMV-MCS-EF1-GFP+puro lentiviral vector purchased from SBI (reference # 
CD513B-1).  These were then packaged into lentiviral particles using HEK293T 
cells.  Constructs expressing wild-type Syk and kinase dead Syk were 
reconstructed using the T-REXTM system to create a tetracycline (Tet) inducible 
system. Grb7 cDNA obtained from the DNASU plasmid repository (plasmid 
#FLH213100.01X) was amplified by PCR and cloned into mCherry vector VQ 
AD5CMV (ViraQuest) between the EcoR1 and XpaI restriction sites. A vector 
coding for Grb7-mCherry(R461M) was generated by site-directed mutagenesis 
using the transformer mutagenesis kit (Clontech), forward primer: 5’ TTC CTG 
GTC ATG GAG AGT CAG CGG A and reverse primer: 5’ GGG GGT TCC GCT  
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GAC TCT CCA TGA CCA G. GST-SH2 domain expression construct of human 
Grb7 cloned into the pGEX6P1 vector was obtained from Addgene (vector 
reference #46444).1  
 
3.2 Cell culture, shRNA knockdowns, and DNA transfections 
  Syk-deficient MCF7 breast cancer cells were purchased from BD 
Biosciences as previously described (insert reference).  MCF7 cells, MDA-MB-
231, DG75 human B lymphoma cells, and BT549 breast cancer cells were 
purchased from the American Type Culture Collection (ATCC). The chicken 
DT40 B cell lines and all DT40 knockout mutant cell lines were a generous gift 
from Dr. Kurasaki from Tokyo, Japan.  The MCF7, BT549, and MDA-MB-231 cell 
lines were cultured in DMEM medium supplemented with 10% FBS (Gibco), 
0.37% sodium bicarbonate, 100 IU/ml penicillin and 100 μg/ml streptomycin. 
DT40 and DG75 cell lines were cultured in RPMI-1640 medium containing 7.5% 
FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, and 50 μg/ml 2-ME.  Media for 
the DT40 cell line was supplemented with 1% chicken serum. Cells were 
maintained in a humidified incubator at 37°C with an atmosphere of 5% CO2 and 
95% air.    
 For generation of cells stably expressing Syk-EGFP, Syk-deficient MCF7 
cells were infected with lentiviruses, selected in media containing 1 μg/ml 
puromycin, expanded and screened for kinase expression by fluorescence 
microscopy and Western blotting.   
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 For Grb7-mCherry expressing cells, MCF7-BD cells stably expressing 
Syk-EGFP were transiently transfected with 1 μg of the expression plasmid 
encoding Grb7-mCherry or Grb7-mCherry(R461M) using lipofectamine 2000 
(Invitrogen).  After 24 h, cells were used for experiments. 
 A MDA-MB-231 cell line with tetracycline-regulated Syk expression was 
constructed using the T-REXTM system (Invitrogen) as previously described 
(insert reference).2  This cell line was used to generate a line with reduced levels 
of MAP1B protein using a set of five TRC small hairpin RNAs (shRNA) that were 
individually packaged into lentiviral particles targeting endogenous MAP1B 
mRNA (Thermo Scientific).  Cells were plated in 10 cm plates at approximately 
70% confluence and infected with each sh-RNA-expressing pLKO.1 lentivirus 
according to the manufacturer’s instructions.  Cells containing integrated lentiviral 
sequences were selected using 1 μg/mL puromycin.  Medium containing 
puromycin was replaced every 24 h until resistant colonies were observed.  
Knockdown of MAP1B was confirmed by immunofluorescence and Western 
blotting using antibodies against MAP1B.  Two of the five purchased shRNAs 
displayed a knockdown phenotype: TRCN 0000226621 and TRCN 000011620.   
 MDA-MB-231 cells were transiently transfected with 1 μg of each 
expression plasmid encoding Syk-EGFP (BD Biosciences), or c-Src (Addgene 





3.3 Antibodies and other reagents 
 The following antibodies were used for immunoblotting and/or 
immunofluorescence: Syk (N19, Santa Cruz), acetylated tubulin (T6793, Sigma), 
 -tubulin (T5168, Sigma) acetylated lysine (9441, Cell Signaling Technologies), 
MAP1B (N-19, Santa Cruz), c-Src (ab47405, Abcam), G3BP (611126,BD 
Biosciences), TIAR (D26E4, Cell Signaling Technology), phosphotyrosine (4G10, 
Millipore), Grb7 (A-12, Santa Cruz), LC3A/B (D3U4C, Cell Signaling 
Technology), GAPDH (AM4300, Ambion), eIF2  (FL-315, Santa Cruz), phospho-
eIF2  (ab32157, AbCam), AlexaFluor 594-conjugated goat anti-mouse IgG 
(Invitrogen), and AlexaFluor 405-conjugated goat anti-rabbit IgG secondary 
antibodies (Invitrogen).  ProLong Gold Antifade reagent was purchased from 
Invitrogen. 
 Z-Leu-Leu-Leu-al (MG132) and sodium arsenite (NaAsO2) were 
purchased from Sigma-Aldrich.  The Src inhibitor 1-(1,1-dimethyllethyl)-3-(4-
methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (PP1) was purchased from 
Cayman Chemical. Autophagy inhibitors 3-methyladenine (3-MA) and N2,N4-
Bis(phenylmethyl)-2,4-quinazolinediamine (DBeQ) were purchased from Sigma-
Aldrich.  Syk-AQL selective inhibitors either 1-(1,1-dimethylethyl)-3-(1-
napthlalenylmethyl)-1H-pyrazolo[3,4-d]pyrimidine-4-amine (1-NM-PP1) or 4-
Amino-1-tert-butyl-3-(3-methylbenzyl)pyrazolo[3,4-d]pyrimidine (3-MB-PP1) were 
purchased from Cayman Chemical and Calbiochem, respectively. 
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3.4 Western blotting 
 Cells were lysed in 1% NP-40 lysis buffer (50 mM Tris-HCl, pH 7.4, 150 
mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 1 mM EGTA, 10% glycerol, 
and protease inhibitor cocktail (65621 AbCam)).  The lysates were centrifuged at 
14,000 X g for 1 min.  Proteins in the supernatant were separated by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and analyzed 
by immunoblotting with the indicated antibodies (section 3.3). 
 
3.5 Co-immunoprecipitation 
 MCF7-BD cells stably expressing Syk-EGFP were lysed in 1% NP-40 lysis 
buffer containing 2 mM Na3VO4.  Syk-EGFP tagged protein was 
immunoprecipitated using GFP-Trap agarose beads (ChromoTek).  Bound 
immune complexes were washed with lysis buffer, separated by SDS-PAGE, and 
analyzed by Western blotting with the indicated antibodies.  For 
immunoprecipitation of stress granule components, cells were lysed in RNA 
stabilization buffer (100 mM KCl, 5 mM MgCl2, 10 mM HEPES pH 7.4, 0.5% 
Triton X-100, 100 U/ml RNase inhibitor, 1 mM dithiothreitol, 1 mM 
phenylmethylsulfonyl fluoride, and protease inhibitor cocktail).  The supernatants 
from the lysates were precleared for 30 min by agitation with a mixture of protein 
A and G magnetic beads purchased from Thermo Scientific.  Cleared lysates 
were incubated with the indicated antibodies bound to magnetic beads.  Immune 
complexes were washed with lysis buffer supplemented with 100 U/ml RNase 
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inhibitor, proteins were in the supernatant were separated by SDS-PAGE and 
analyzed by Western blotting. 
 
3.6 Grb7 SH2 domain pull down  
 The GST-SH2 domain of Grb7 was expressed in and isolated from E. coli 
by adsorption onto glutathione-agarose.  Immobilized GST-SH2 (~10 μg of 
protein) was incubated with lysates of MCF7 cells expressing either Syk-EGFP or 
Syk-EGFP(Y342F/Y346F) and then washed extensively with 50 mM Tris-HCl, pH 
7.5, 150 mM NaCl, 10% glycerol, and 1% NP-40.  Bound proteins were eluted in 
SDS-sample buffer and detected by Western blotting.   
 
3.7 Immunofluorescence microscopy 
Cells (5x105) cultured on coverslips were fixed with cold methanol for 10 min and 
permeabilized with 0.01% Triton X-100 in PBS buffer containing 10% goat 
serum.  This same buffer was used as blocking buffer. Cells on coverslips were 
immunostained with the indicated antibodies.  Bound primary antibodies were 
detected using an AlexaFlour 594-conjugated goat antimouse IgG secondary 
antibody and/or AlexaFluor 405-conjugated goat anti-rabbit IgG secondary 
antibody (Invitrogen).  Coverslips were mounted with ProLong Gold Antifade 
reagent (Invitrogen) for fluorescence and confocal microscopy.  Slides were 
examined by an Olympus BH2-RFCA fluorescence microscope with a 60X 
objective equipped with a Sony DXC-950 3CCD color camera and Northern 
91 
Eclipse version 5.0 from Empix Imaging (Mississauga, ON), an EVOS FL 
imaging system, and/or a Zeiss LSM 710 confocal microscope.   
 
3.8 Cellular fractionation 
 For the preparation of cell fractions based on detergent solubility, cells 
were lysed in 1% NP-40 lysis buffer.  The detergent-soluble fraction was 
separated from the insoluble fraction by centrifugation for 1 min at 18,000 X g.  
The insoluble fraction was resuspended in the lysis buffer supplemented with 1% 
SDS.  Proteins in the supernatants of each fraction were separated by SDS-
PAGE and analyzed by Western blotting with the indicated antibodies. 
 
3.9 Microtubule stability experiments 
 MDA-MB-231 cells either expressing or lacking Syk-EGFP or BT549 cells 
transfected to overexpress c-Src were cultured on coverslips and treated with 10 
μM nocodazole for 30 min.  Cells were fixed with cold methanol for 10 min, 
permeabilized, blocked, and immunostained with antibody against -tubulin.  
Microscopic images generated by fluorescence microscopy of cells that were 
immunostained for -tubulin were measured to assess microtubule stability.  The 
length of the residual microtubule network extending from the nucleus to the 
furthest exterior edge of the cell was measured.   
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3.10 Stress granule formation and clearance 
 To induce the formation of stress granules, cells were treated with either 
500 μM sodium arsenite for 2 h or 100 μM MG132 (Sigma-Aldrich) for 3 h.  For 
some experiments, cells were pretreated with 20 nM Src inhibitor PP1 (Cayman 
Chemical) for 15 min prior to the induction of stress granule formation.   MCF7-
BD cells stably expressing Syk-AQL-EGFP were selectively inhibited during 
stress granule formation or clearance by the addition of either 5 μM 1-NM-PP1 
(Cayman Chemical) or 3-MB-PP1 (Calbiochem).  For stress granule clearance 
assays, MCF7-BD cells stably expressing either wild type or mutant forms of 
Syk-EGFP were treated with MG132 for 3 h and then washed with fresh DMEM 
media and allowed to recover in fresh media in the absence of the drug for an 
additional 4 h.  For autophagy experiments, autophagy inhibitors 3-MA (5 mM) or 
DBeQ (10 μM) were added during stress granule clearance at the times 
indicated.   
3.11 Cellular proliferation assay (MTT) 
 An MTT assay was performed to assess the number of viable MCF7-BD 
cells either expressing or lacking Syk-EGFP.  Cells were plated into a 96-well 
plate 24 h prior to treatment with 1 μM sodium arsenite for 24 h. Thiazolyl Blue 
Tetrazolium Bromide (0.5 mg/ml) purchased from Sigma-Aldrich was added for 2 
h.  Cells were then washed with PBS, and dissolved in DMSO.  Absorbance was 
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CHAPTER 4. NANOMECHANICAL PROPERTY MAPS OF BREAST CANCER 
CELLS AS DETERMINED BY MULTIHARMONIC ATOMIC FORCE 
MICROSCOPY REVEAL SYK-DEPENDENT CHANGES IN MICROTUBULE 





 Recent advances in the use of atomic force microscopy (AFM) to record 
nanomechanical properties of live cells in liquid media make it possible to map 
quantitatively heterogeneous differences in cellular topography, elasticity, and 
viscosity at high resolution.1 For example, local property maps of rat fibroblasts 
using multiharmonic AFM are sufficiently detailed for visualization of components 
and properties of the actin cytoskeleton.1 Unlike conventional quasi-static 
techniques in which the bending of the cantilever probe is monitored as a 
function of indentation into the cell at each pixel, multiharmonic AFM is a 
dynamic AFM method in which the cantilever probe is excited by Lorentz forces 
and changes in amplitude, the phase of the oscillator, and other relevant 
harmonics are converted into quantitative local property maps.1 This mode works 
in the amplitude modulation (AM-AFM) scheme in which the oscillation amplitude 
is regulated as the probe scans over the cell. Changes in the physical properties 
of cells caused by rearrangements in cytoskeletal networks underlie the ability of  
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cancer cells to progress from a static phenotype to a metastatic phenotype.2 This 
process is, in turn, controlled by signaling cascades regulated through multiple 
effectors, including the protein tyrosine kinase Syk but the mechanisms involved 
are poorly understood.3-6 In this study, we examined the utility of multiharmonic 
AFM for the characterization of Syk-dependent changes in the physical 
properties of cancer cells as a method of both quantifying physical differences in 
cells expressing or lacking the kinase and identifying the underlying mechanisms. 
 Syk is a 72 kDa protein-tyrosine kinase and well-characterized component 
of the apparatus required for transducing signals initiated by the activation of 
immune recognition receptors in the innate and adaptive immune systems.7,8 
While a critical role for Syk in immune cell function is clear, a less familiar role in 
the progression of cancer cells of nonhematopoietic origins has become evident. 
Syk has been described both as a tumor promoter on the basis of its prosurvival 
functions in Ras-transformed pancreatic and lung cancer cells and 
retinoblastoma and as a tumor suppressor on the basis of its loss from many 
highly invasive tumor cells.5,9-17 For example, while Syk is present in relatively 
nonaggressive breast cancer cells and cell lines, it is absent from cancer cells 
with a highly invasive, metastatic phenotype.10  Reintroduction of the kinase into 
malignant breast carcinomas inhibits their motility, invasion, and metastasis.10,18  
Similarly, the loss of Syk from relatively noninvasive breast epithelial cells 
decreases the number of cell cell junctions, enhances cell motility and invasion, 
and promotes the conversion of cells from an epithelial phenotype to a 
mesenchymal phenotype.6,18  Changes in the mechanical properties of tumor 
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cells that accompany an epithelial to mesenchymal transition (EMT) require 
rearrangements in their cytoskeletal networks, involving both microtubules and 
microfilaments.2,19,20  In general, cells move through an extension of lamellipodia 
at the front of the cell driven primarily by actin polymerization and retraction of 
the trailing edge driven by dynamic microtubules that target focal adhesions to 
trigger their disassembly.20,21  Thus, dynamic rearrangements in both structural 
networks are required for malignant cells to move and metastasize. 
Consequently, critical components of malignant transformation and metastasis 
include changes in a cell’ s mechanical phenotype, including elasticity, viscosity, 
adhesion, and force generation.22,23   
 To begin to explore Syk-dependent changes in the mechanical properties 
of tumor cells, we examined cells expressing or lacking the kinase using AFM to 
map the topography and mechanical properties of live cells. Interestingly, we 
found that the expression of Syk in highly invasive breast carcinoma cells 
dramatically reduced cell height, increased elasticity, increased viscosity, and 
allowed visualization of a more substantial microtubule network. Consistent with 
these observations, the microtubules of Syk-expressing cells were more stable to 
nocodazole-induced depolymerization and were more highly acetylated than 
those of Syk-deficient cells. This effect of Syk on microtubule stability, which 
required protein phosphorylation, was modulated, in part, through the 
microtubule-associated protein, MAP1B, a major substrate for Syk in MDA-MB-
231 tumor cells.24  
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 Consequently, down modulation of MAP1B levels in cells attenuated the Syk-
dependent increase in microtubule stability and reversed much of the effect of 
Syk expression on the nanomechanical properties of invasive cancer cells. 
 
4.2 Multiharmonic AFM Mapping of Physical Properties of Breast Cancer Cells 
 Tumor suppressor functions attributed to Syk reflect its ability to inhibit 
motility and metastasis when re-expressed in highly invasive cancer cells.10,18  
Because the molecular mechanisms underlying this property are poorly 
understood, we examined how the expression of Syk would affect the physical 
properties of an invasive breast cancer cell line. MDA-MB-231 cells have a 
mesenchymal phenotype, are highly motile, and readily form metastases upon 
being introduced into mice.36  The expression of exogenous Syk in metastatic 
breast cancer cells inhibits their motility and markedly attenuates the formation of 
distant metastases.10  We generated a stable line of MDA-MB-231 cells in which 
the expression of Syk with a C-terminally enhanced green fluorescent protein tag 
(Syk-EGFP) was under the control of a tetracycline-inducible promoter.18  These 
cells lack endogenous Syk but, upon being treated with tetracycline, express 
Syk-EGFP. 
 As shown previously, the expression of Syk-EGFP in MDAMB-231 cells 
markedly attenuates their motility.18  To begin to explore possible mechanisms by 
which Syk influences the properties of MDA-MB-231 cells, we used 
multiharmonic AFM to image at high spatiotemporal resolution live cells either 
lacking Syk or induced to express Syk-EGFP. In multiharmonic AFM, a 
98 
microcantilever is excited near the natural first flexural frequency, pressed down 
against the cell, and scanned across the cell to collect the resulting changes in 
the vibration harmonic content, which represents changes in nanomechanical 
physical properties of the cells.1  The topography and nanoscale compositional 
contrast images [mean cantilever deflection or the zeroth harmonic (A0) and first 
harmonic phase lag ( 1)] for a typical pair of cells are illustrated in Figure 4.1. 
Second harmonics were not observed on these cells. The compositional contrast 
images of cells lacking Syk (Figure 4.1 A C) exhibit very few cellular features 
and no well-defined cytoskeletal organization consistent with the nature of these 
cells, which are highly motile with a dynamic internal cytoskeleton. These cells 
exhibited a rounded phenotype and were often removed easily from the gelatin-
coated dish during scanning likely because of their high level of motility and 
decreased strength of adhesion. In contrast, the cells expressing Syk-EGFP 
were characterized by an increased level of cell spreading (decreased cell 
height) and a more organized subsurface cytoskeletal structure (Figure 4.1, 
bottom panels). Syk-EGFP-expressing cells also were less likely to evade the 
cantilever, because of decreased motility and increased adhesion. The measured 
compositional contrast images A0 and 1 were combined to extract the local 
nanomechanical properties, specifically the stiff ness and damping of local 





ksample is a measurement of the differences in stiffness or rigidity within the cell, 
and csample  illustrates differences in the damping or cell viscosity (Figure 4.1; a 
second example is illustrated in Figure 4.2).1,27 The induction of Syk-EGFP 
expression in MDA-MB-231 cells dramatically increased both cell stiffness and 
viscosity. 
 
4.3 Effects of Syk on Microtubule Stability 
 The actin and microtubule cytoskeletons provide the intracellular networks 
that determine many of the physical properties of cells.37,38  AFM compositional 
contrast images of cells expressing Syk- EGFP revealed subcellular structures 
consistent with that of a cytoskeletal network (Figure 4.1, bottom panels). The 
size and morphology of this network were more consistent with those of 
microtubules than those of actin microfilaments when compared to images of 
cells stained with antibodies against -tubulin or labeled with rhodamine-
phalloidin (Figure 4.3).  F-Actin staining was observed primary at the cell cortex, 
while microtubule polymers were found throughout the cytoplasm and resembled 










 To study in more detail possible effects of Syk on microtubules, we 
examined the stability of the microtubule network. MDA-MB-231 cells either 
lacking or expressing Syk-EGFP were treated with low concentrations of 
nocodazole for 30 min to promote microtubule depolymerization. It has been 
shown that differences in the stability of the microtubule network manifest 
themselves as changes in resistance to nocodazole-induced depolymerization.39  
Cells were fixed and stained with an antibody against -tubulin and examined by 
fluorescence microscopy. There was a pronounced difference in the morphology. 
of the nocodazole-treated cells between those lacking Syk, in which the 
microtubule network was largely disassembled, and those expressing Syk-EGFP, 
in which cells retained microtubule structures resistant to drug-induced 
depolymerization (Figure 4.4A). To quantify these differences, we determined the 
persistence of the microtubule network by measuring the distance of -tubulin 
staining from the nucleus to the perimeter of each cell. Results from a 
comparison of more than 200 cells are shown in Figure 4.4B. Nocodazole treated 
cells expressing Syk-EGFP exhibited a much greater level of retention of -
tubulin-containing polymers than did cells lacking Syk. In contrast to the 
expression of Syk, the overexpression of c-Src, which typically enhances cell 
motility, failed to prevent cells from rounding up following treatment with 






 Because MDA-MB-231 cells are somewhat unique among breast cancer 
cell lines in that they express activated K-Ras, we also examined the effects of 
Syk expression in BT549 human breast carcinoma cells, which do not express 
activated K-Ras and also lack endogenous Syk.10  Again, the expression in these 
cells of Syk stabilized the microtubule networks and inhibited the rounding up of 
cells in response to nocodazole, similar to the results observed for MDA-MB-231 
cells (Figure 4.6).  
 A hallmark of stable microtubules is an increase in their extent of 
acetylation on lysine.41  Consequently, we asked if tubulin from Syk-EGFP-
expressing cells was more highly acetylated than tubulin from cells lacking Syk. 
MDA-MB-231 cells either not induced or induced to express Syk-EGFP (Figure 
4.7A) were lysed in microtubule stabilizing buffer containing 1% NP-40 and 
separated by centrifugation into soluble (monomer) and insoluble (polymer) 
fractions. Proteins in each fraction were separated by SDS  PAGE and analyzed 








Acetylated tubulin was found predominantly in the polymer fraction as expected 
(Figure 4.7B). Tubulin from Syk-EGFP-expressing cells contained an 
approximately 3-fold higher level of acetylated lysine, consistent with the 
increased stability of the microtubule network in these cells. An increase in the 
level of highly acetylated microtubules in the Syk-EGFP expressing cells was 
confirmed by immunofluorescence microscopy (Figure 4.8C). When treated with 
nocodazole, the Syk-EGFP-expressing cells also retained more lysine-acetylated 
microtubule polymers than cells lacking Syk-EGFP. Similar results were 
observed in MDA-MB-231 cells transiently transfected to express Syk-EGFP as 
compared to Syk-deficient cells (Figure 4.9).  
 
4.4 Role of Phosphorylation in the Stabilization of Microtubules 
 To determine if Syk-dependent protein phosphorylation was involved in 
modulating cytoskeletal dynamics, we asked if the catalytic activity of Syk was 
required for the promotion of microtubule stability. We generated a line of MDA-
MB-231 cells in which the expression of a catalytically inactive version of Syk-
EGFP [Syk-EGFP(K396R)] was under the control of a tetracycline-inducible 
promoter. Cells induced to express Syk-EGFP or Syk-EGFP(K396R) were 
treated with nocodazole (10 μM) for 30 min, fixed, immunostained with an -
tubulin antibody, and examined under the fluorescence microscope. There was 
an obvious difference in the morphology of drug-treated cells expressing active 





As compared to cells expressing Syk-EGFP, Syk-EGFP(K396R)-expressing cells 
were more rounded because of microtubule depolymerization and resembled 
cells that lacked Syk. Thus, the ability of Syk to stabilize microtubules was a 
function of its catalytic activity. 
 
4.5 Identification of a Syk Substrate Involved in Microtubule Stability 
 To investigate how active Syk might promote microtubule stability, we 
searched for proteins from MDA-MB-231 cells that were both phosphorylated on 
tyrosine in a manner dependent on the exogenous expression of Syk and 
involved in the stabilization of microtubules. The results of this large-scale 
phosphoproteomic analysis of Syk-dependent phosphorylated substrates were 
published recently.24 
 Among the Syk-dependent phosphoproteins identified in our study was 
MAP1B, a microtubule-associated protein known to enhance microtubule 
stability.41-43 We identified 17 distinct sites of tyrosine phosphorylation on MAP1B 
isolated from MDA-MB-231 cells expressing exogenous Syk that were not 
phosphorylated in cells lacking the kinase.24  Ten of these sites were also 
phosphorylated on MAP1B isolated from DG75 B lymphoma cells, which are 
cells that express endogenous Syk at normal levels. Multiple MAP1B derived 
phosphopeptides were also identified when tyrosine phosphorylated tryptic 
peptides from MDA-MB-231 or DG75 cells were isolated, dephosphorylated in 
vitro, and then rephosphorylated by recombinant Syk.44  Many of these sites are 
clustered within an area known as the imperfect repeat region (Table 4.1).45,46 
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4.6 Effect of the Depletion of MAP1B on Microtubule Stability 
 To determine if MAP1B was critically involved in microtubule stabilization 
in MDA-MB-231 cells, we reduced the level of the protein through RNA 
interference. A collection of five different lentiviruses were used individually to 
deliver small hairpin RNAs (shRNAs) targeting MAP1B to MDA-MB-231 cells 
either expressing or lacking Syk-EGFP. Two of the five shRNAs successfully 
reduced the level of MAP1B as measured by the immunofluorescence of infected 
and antibiotic-selected cells (an example of one of these is illustrated in Figure 
4.11) or by Western blotting (Figure 4.12). To ascertain a role for MAP1B in Syk-
dependent microtubule stability, we induced the expression of Syk-EGFP in 
MDA-MB-231 cells expressing normal or reduced levels of MAP1B. Cells were 
treated with nocodazole (10 μM) for 30 min, fixed, and immunostained using an 
antibody against -tubulin (Figure 4.13A). The size of the drug-resistant 
microtubule cytoskeleton was then measured (Figure 4.13B). Despite the 
expression of Syk-EGFP, the MAP1B knockdown cells displayed a morphology 
similar to that of cells lacking Syk as cells were more rounded and failed to retain 
stable microtubule networks. 
 
4.7 Influence of MAP1B on the Physical Properties of MDA-MB-231 Cells 
 To investigate roles for Syk in conjunction with MAP1B in modulating the 
physical properties of cancer cells, we measured the influence of Syk on the 
topography and elasticity of MDA-MB-231 cancer cells in the presence or 





using the force  volume (F V) mode to compare changes in the relative elastic 
modulus. In F V imaging, the AFM probe approaches, is pushed against, and is 
retracted from the cell surface on a grid of points predefined by the user to record 
a resulting force  distance curve. Subsequently, the images are processed 
offline to extract two quantities of interest: cell height and elasticity.  A second 
example is shown in Figure 4.14. The respective topography maps are shown in 
the top panels and elasticity maps in the bottom panels. The comparative 
maximal cell height and elasticity histograms in the nuclear region from multiple 
cells are illustrated in panels A and B of Figure 4.15, respectively. The induction 
of Syk-EGFP expression in MDA-MB-231 cells dramatically decreased the height 
of the average cell from 5.62 ± 1.58 to 3.83 ± 1.26 μm. The cell height was 
increased to 4.87 ± 1.22 μm by decreasing the intracellular level of MAP1B in the 
Syk-EGFP-expressing cells. Similarly, the expression of Syk-EGFP increased the 
cellular elasticity from 0.488 ± 0.199 to 1.35 ± 0.387 kPa. Again, the knockdown 
of MAP1B partially reversed this eff ect, reducing the elasticity of Syk-expressing 
cells to 0.812 ±  0.224 kPa. 
 These results indicate that the expression of Syk has pronounced effects 
on the physical properties of MDA-MB- 231 cells (decreased height and 
increased stiff ness) and that these are mediated in part, but not in full, by the 
phosphorylation of MAP1B. Thus, many of the changes in the physical properties 
of MDA-MB-231 cells resulting from the expression of Syk are mediated by 






 To disseminate from the site of a primary tumor, a cancer cell of epithelial 
origin must detach from neighboring cells, migrate from the tumor site, 
extravasate into either the vascular or lymphatic systems, travel to a distant site, 
extravasate from the circulation, and establish through cell division a new tumor 
Mass.3,4,47 To accomplish this, transformed epithelial cells undergo EMT, 
whereby they lose E-cadherin-mediated contacts, develop strong cell  
extracellular matrix adhesions, and undergo cytoskeletal rearrangements that 
allow them to achieve enhanced migratory and invasive properties.48  
Considerable work has been done using AFM to measure variations in 
mechanical properties as a function of metastatic potential, allowing the detection 
of tumor progression. The resulting changes in the mechanical properties of 
tumor cells that accompany EMT as measured by AFM include decreased 
stiffness, consistent with many observations that cancer cells exhibit an elasticity 
significantly decreased in comparison to those of their normal counterparts.38,49  
Prior work has shown that metastatic cancer cells are more than 70% softer than 
benign cells.50  A decrease in the Young’ s moduli has been reported for prostate 
cancer cells with increasing metastatic potential.51  The inhibition or knockdown 
of Syk in breast epithelial cells or Ras-dependent pancreatic carcinomas induces 
phenotypic changes characteristic of EMT.5,6 Consistent with these observations, 
the re-expression of Syk in highly invasive MDA-MB-231 cells, which have a 
mesenchymal phenotype, substantially decreases cellular elasticity and 
increases viscosity and the level of adhesion. 
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 The intrinsic stiff ness of cells is a property of cellular cytoskeletal 
networks including microtubules and actin microfilaments. The appearance of 
subcellular structures resembling microtubules revealed by AFM selectively in 
Syk-expressing cells prompted us to explore the effects of the kinase on tubulin 
polymers. Microtubules were more stable in Syk-expressing cells as measured 
by their insensitivity to drug-induced depolymerization and an increased content 
of acetylated lysine, which is a marker of more stable microtubules. Several 
studies have demonstrated interactions between Syk and microtubules or 
proteins involved in the regulation of microtubule organization. Syk can bind to 
and phosphorylate tubulin, and a fraction of the kinase localizes to centrosomes 
and associates with a number of centrosomal proteins.44,52,53 The movement of 
Syk to the centrosome is dependent on both the catalytic activity of Syk and its 
movement along microtubules mediated by the dynein dynactin complex.54  A 
phosphoproteomic analysis of Syk-dependent substrates identified several 
centrosomal and microtubule-associated proteins.24,44  The substrate with the 
most identified sites of phosphorylation was MAP1B, a microtubule-associated 
protein found most prominently in the nervous system.55  The expression of 
MAP1B in MDA-MB-231 cells was unexpected. However, the abnormal 
expression of tissue differentiation markers has been noted previously in many 
cancer cells, including MDA-MB-231 and other breast cancer cells.56  We also 
detected the phosphorylation of MAP1B on multiple tyrosines in DG75 cells, an 
EBV-transformed human B cell lymphoma cell line unrelated to MDA-MB-231.24  
On the basis of the Phospho-SitePlus database, phosphotyrosine-containing 
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peptides derived from MAP1B also have been identified in a variety of tumor cell 
types, including bladder, colorectal, non-small lung, esophageal, Hodgkin’s 
lymphoma, and chronic myelogenous leukemia.57 
 MAP1B is developmentally regulated in the nervous system where it plays 
an important role in neurite and axon extension through its ability to bind to 
dynamic microtubules in growth cones.43,58-60  The exogenous expression of 
MAP1B in nonneuronal cells stabilizes microtubules to drug-induced 
depolymerization and increases the abundance of acetylated microtubules.41,61 
When present in MDA-MB-231 cells, these activities of MAP1B are enhanced 
considerably by the coexpression of Syk, which phosphorylates the protein on 
multiple tyrosines. MAP1B has previously been shown to be extensively 
phosphorylated by serine/threonine kinases on a variety of sites spread out 
throughout the central region of the molecule.62  Phosphorylation has been 
shown to modulate the ability of the protein to bind to and stabilize microtubules 
depending on the site or sites that are modified.62 The sites phosphorylated by 
Syk are largely clustered within the hydrophilic imperfect repeat region of 
MAP1B, a region not directly involved in binding microtubules.46  This region 
contains multiple consensus sites of serine phosphorylation for casein kinase 2 
(CK2), which phosphorylates MAP1B and enhances its binding to 
microtubules.63,64  It is reasonable to predict that the phosphorylation of MAP1B 
by Syk within this same acidic region would also enhance MAP1B  microtubule 
interactions, accounting for the ability of Syk to promote microtubule stability. 
Interestingly, three of these sites are found within pYXXL/I motifs, which are 
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sequences recognized by a subset of SH2 domain-containing proteins, including 
Syk itself. Such an interaction may help explain the abundance of tyrosines on 
MAP1B that become phosphorylated in cells expressing both MAP1B and Syk. 
Because dynamic microtubules play major roles in motility by modulating the 
disassembly of focal adhesions and retraction of the trailing edge of migrating 
cells, increased stability conferred by the enhanced binding of phosphorylated 
MAP1B could reasonably account for many aspects of Syk’ s ability to limit the 
motility of highly invasive cancer cells. It is interesting that modulation of the 
activity of a microtubule-stabilizing factor produces such dramatic changes in the 
mechanical properties of cancer cells as changes in the stiff ness of cells are 
most often attributed to alterations in the actin cytoskeleton.38,65,66 However, 
there is considerable cross-talk between cytoskeletal systems. For example, Rho 
family GTPases, which control actin dynamics, are, in turn, regulated by dynamic 
microtubules that interact in a polymerization-dependent fashion with Rho 
guanine nucleotide exchange factor 190RhoGEF.67 Thus, dynamic microtubules 
are major modulators of the mechanical properties that affect fundamental 
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CHAPTER 5. SYK IS RECRUITED TO STRESS GRANULES AND PROMOTES 





 The Syk protein-tyrosine kinase is best known for its many roles in the 
adaptive and innate immune systems as a component of the molecular 
machinery that couples immune recognition receptors to intracellular signaling 
pathways in multiple hematopoietic cell types including B cells, mast cells, 
platelets, NK cells, macrophages, and neutrophils.1,2  In these cells, receptor 
engagement leads to the phosphorylation of a pair of tyrosines present within 
immunoreceptor tyrosine-based activation motifs (ITAMs) on receptor 
components, which leads to the recruitment of Syk to the receptor and its 
subsequent activation.  The participation of Syk in pro-inflammatory signaling 
events has led to considerable interest in the use of small molecule Syk inhibitors 
for the treatment of diseases such as allergic asthma, rheumatoid arthritis and  
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systemic lupus erythematosus.3  The identification of additional roles for Syk in 
tumorigenesis has increased interest in the use of Syk inhibitors as 
chemotherapeutic agents for the treatment of disorders in which the expression 
of Syk serves as a pro-survival factor.4  The inhibition of or knockdown in 
expression of Syk promotes apoptosis in multiple cancer cell types including 
many hematopoietic malignancies as well as K-Ras-dependent lung and 
pancreatic cancer, small cell lung cancer, ovarian cancer and retinoblastoma.5-8  
For many cancer cells, the expression of Syk can protect them from cell death 
due to genotoxic or oxidative stress.9  
 Eukaryotic cells respond to external stresses in a variety of ways including 
the reprogramming of translational processes.10,11  Insults due to heat shock, 
viral infection, oxidative stress, exposure to arsenite, or glucose deprivation 
activate kinases that phosphorylate eIF2  to stall translation of mRNAs bound to 
initiation complexes and promote polysome disassembly. Messenger RNAs are 
rerouted along with their associated proteins into stress granules (SGs), large 
ribonucleoprotein (RNP) complexes scaffolded by RNA binding proteins with 
glycine-rich self-associating domains. Cytoplasmic poly(A) mRNAs stalled in the 
translational initiation phase are sequestered in SGs and potentially protected 
from degradation until stress is released and normal protein synthesis can 
resume.  SGs also can sequester signaling molecules important for apoptosis 
and contribute in this fashion to the protection of cells from stress.12,13   
 The formation of RNP aggregates, however, also can be detrimental to 
cell survival.  This is particularly apparent within the nervous system where 
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mutations in RNPs that promote self-assembly can be major drivers of 
neurodegenerative diseases.14-17  Similarly, defective clearance of SGs leads to 
the pathological accumulation of RNP particles.18,19  Genetic studies of regulators 
of SG dynamics in yeast identified granulophagy, a form of macroautophagy 
(referred to here simply as autophagy), functioning in conjunction with 
Cdc48/valosin-containing protein (VCP), as critical for SG clearance.20  Mutations 
in VCP are known to cause amyotrophic lateral sclerosis and frontotemporal 
dementia, consistent with a role for defects in SG clearance in disease 
pathology.18,19  VCP also is upregulated in many human cancers; and tumor cells 
use autophagy as a survival strategy when encountering external stresses due to 
increased metabolic demands, a challenging microenvironment, or exposure to 
therapeutic agents.21-27   
 To better understand the prosurvival pathways in which Syk functions, we 
conducted a series of proteomic analyses to identify substrates and interacting 
partners of the kinase.28-30  Among the binding partners we identified were 
several with functions in mRNA metabolism that are known to associate with 
SGs.  This finding raised the interesting possibility that Syk also associates with 
SGs and plays a role in SG function or dynamics.  In this study, we demonstrate 
that Syk is, in fact, recruited to SGs in response to the treatment of cells with 
either sodium arsenite or a proteosome inhibitor, both of which are known 
inducers of SG formation.31  This recruitment requires the phosphorylation of a 
pair of tyrosines on Syk located in a region where the kinase interacts with the 
SG component, Grb7.  In SGs, Syk is active and catalyzes the phosphorylation of 
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proteins on tyrosine.  Interestingly, the recruitment of Syk to SGs promotes their 
clearance from cells through autophagy and enhances the survival of cells in 
which SGs are induced.  This previously unknown function of Syk may underlie 
many aspects of its ability to promote the survival of cancer cells in the presence 
of metabolic or therapeutic stress.   
 
5.2 Syk is recruited to SGs  
 Previous Syk-dependent substrate and interactive partner screens from 
our laboratory identified multiple proteins mapped to specific complexes or 
pathways involved in mRNA dynamics.28-30  Specifically, we identified as Syk-
interacting proteins an extensive set of SG components including G3BP, a known 
scaffolding protein necessary for SG formation (Table 5.1).10,29,37-42 To 
investigate a possible direct association of Syk with SGs, we asked whether Syk 
was recruited to SGs under conditions that promoted their formation.  We treated 
a line of MCF7 cells that lacks endogenous Syk (MCF7-BD), but stably 
expresses Syk-EGFP, with either the proteosome inhibitor MG132 for 3 hours or 
sodium arsenite for 2 hours.34  Cells were fixed and stained with an antibody 
against G3BP and examined by fluorescence microscopy.  Both treatments 
resulted in the formation of cytoplasmic puncta containing G3BP consistent with 
the formation of SGs. A fraction of Syk-EGFP co-localized with G3BP-containing 
bodies in cells treated with either stimulus (Fig. 5.1).  Syk-EGFP also colocalized 








Syk-EGFP also was recruited to G3BP-containing puncta in Syk-EGFP-
expressing DT40 lymphoma cells treated with MG132; and endogenous Syk 
colocalized with TIAR in human DG75 B lymphoma cells treated with sodium 
arsenite (Fig. 5.2B and 5.3).   
 A redistribution of Syk within the cell following the induction of SGs also 
was examined biochemically.  MCF7-BD cells stably expressing Syk-EGFP were 
treated with MG132 to induce SG formation.  At timed intervals, cells were lysed 
and separated into detergent-soluble and insoluble fractions.  Western blot 
analyses demonstrated an increased level of Syk-EGFP in the detergent-
insoluble fraction following the addition of MG132 (Fig. 5.4).  The accumulation of 
Syk-EGFP in the insoluble fraction increased at each time point over the four-
hour treatment period.  Increased levels of eIF2a also appeared in the insoluble 
fraction as a function of treatment time.  The level of Syk-EGFP in MG132-
induced cytoplasmic puncta continued to increase over an extended 12-hour time 
period as detected by fluorescence microscopy (Fig 5.5).   
 To further confirm a recruitment of Syk to SGs, we immunoprecipitated 
G3BP from lysates of Syk-EGFP-expressing MCF7-BD cells that had been 
treated with sodium arsenite to induce SG formation.  The anti-G3BP immune 
complexes were separated by SDS-PAGE and examined for the presence of 
Syk-EGFP by Western blotting.  We observed a time-dependent association of 
Syk with G3BP in arsenite-treated cells (Fig. 5.6A), consistent with the two 






Similarly, we found Syk-EGFP in anti-G3BP immune complexes isolated from 
lysates of cells treated with MG132 (Fig. 5.6B).  Thus, evidence from both 
biochemical and fluorescence microscopy approaches indicated that Syk was 
actively recruited to SGs and was particularly prevalent in SGs formed during 
prolonged exposure to stress-inducing agents. 
 
5.3 Syk is active in SGs 
 To determine if Syk was active when recruited to SGs, we monitored by 
Western blotting Syk-dependent protein phosphorylation in cells induced to form 
SGs by treatment with either sodium arsenite or MG132.  For these studies, we 
used a line of MCF7-BD cells in which the expression of Syk-EGFP could be 
induced with tetracycline.32  Cells either treated or not treated with tetracycline 
were exposed to sodium arsenite for increasing lengths of time.  Western blotting 
analyses of whole cell lysates with antibodies against phosphotyrosine revealed 
a pronounced increase in the level of tyrosine-phosphorylated proteins 
selectively in cells induced to express Syk-EGFP (Fig. 5.7).  An examination of 
Syk-EGFP immunoprecipitated from cells and examined by Western blot with 
phosphotyrosine antibodies confirmed that Syk itself was phosphorylated on 
tyrosine in cells treated with sodium arsenite (Fig. 5.8A).  An increase in the 
tyrosine-phosphorylation of Syk also was observed in cells treated with MG132 
(Fig. 5.8B).   
 We next asked if the phosphorylation on tyrosine of proteins within SGs 





expressing Syk-EGFP were left untreated or were treated with either MG132 or 
sodium arsenite, fixed, stained using antibodies against phosphotyrosine and 
TIAR, and examined by confocal microscopy.  There was a significant increase in 
a punctate pattern of phosphotyrosine staining in cells stably expressing Syk-
EGFP when treated with either MG132 (Fig. 5.9) or sodium arsenite (Figure 
5.10).  These puncta co-localized with structures containing both TIAR and Syk-
EGFP, confirming the identification of these as SGs.  This enhanced tyrosine-
phosphorylation was largely dependent on the expression of Syk-EGFP.  To 
confirm that this phosphorylation within SGs was specifically dependent on Syk 
and its catalytic activity, we compared MCF7-BD cells stably expressing Syk-
EGFP to cells expressing an analog-sensitive form of Syk-EGFP (Syk-AQL-
EGFP).33 Syk-AQL is an engineered form of Syk with mutations within the ATP-
binding site that make it uniquely sensitive to inhibition by analogs of PP1 that 
have bulky side chains that preclude their binding to the wild-type kinase.43  Both 
sets of cells were pretreated with 1-NM-PP1, a selective orthogonal inhibitor of 
Syk-AQL-EGFP, and then treated with MG132 for three hours to induce SG 
formation.  Cells were fixed and stained using antibodies against 
phosphotyrosine and TIAR (Fig. 5.11).  The increase in tyrosine phosphorylation 
stimulated by MG132 was largely inhibited by 1-NM-PP1 in cells expressing Syk-
AQL-EGFP, but not in cells expressing Syk-EGFP, which is not sensitive to the 
inhibitor.  Thus, the enhanced phosphorylation of proteins within SGs in cells 







5.4 Recruitment of Syk to SGs requires its phosphorylation 
 Despite the low level of SG-associated phosphotyrosine observed in cells 
expressing Syk-AQL-EGFP and pretreated with 1-NM-PP1, the inhibited kinase 
was still localized in SGs (Fig. 5.11).  This suggested that the recruitment of Syk 
to SGs or its retention there might not be dependent on its catalytic activity.  To 
assess this, we compared MCF7-BD cells stably expressing wild-type Syk-EGFP 
to those expressing a catalytically inactive mutant, Syk-EGFP(K396R).  Both 
active and catalytically inactive forms of Syk-EGFP co-localized with G3BP in 
SGs when cells were treated with MG132 (Fig. 5.12).  Thus, the kinase activity of 
Syk was not required for its association with SG components. 
 When activated, Syk becomes phosphorylated on multiple residues 
including tyrosines 342 and 346 (based on the murine Syk numbering system), 
which are found in the linker B region that separates the tandem pair of SH2 
domains from the catalytic domain.1 These residues, when phosphorylated, 
serve as multi-functional docking sites that mediate interactions with several 
proteins that contain SH2 domains.1,2  To assess if these tyrosines played a role 
in the association of Syk with SGs, we generated MCF7-BD cells expressing 
forms of Syk-EGFP in which one or both tyrosines were replaced by 
phenylalanine.  Cell lines were generated that stably expressed Syk-
EGFP(Y342F/Y346F), Syk-EGFP(Y342F) or Syk-EGFP(Y346F).  These were 
treated with MG132 for three hours and then fixed and stained for G3BP to mark 
SGs.  Unlike Syk-EGFP, Syk-EGFP(Y342F/Y346F) largely failed to localize to 






Similarly, the colocalization with G3BP in SGs of both single point mutants of the 
kinase was defective (Fig. 5.14).  Thus, the phosphorylation of both linker B 
tyrosines 342 and 346 was important for the recruitment of Syk to SGs.   
 Since the linker B tyrosines on Syk are phosphorylated in B cells either by 
autophosphorylation or by Src-family kinases, we examined the effects of a Src-
family kinase inhibitor on the recruitment of Syk to SGs.44  MCF7-BD cells stably 
expressing Syk-EGFP were incubated with the Src-kinase inhibitor PP1 for 15 
minutes prior to the induction of SG formation by the addition of MG132.  We 
quantified the fluorescence intensity of Syk-EGFP and G3BP in the puncta that 
contained both proteins, comparing the control and PP1-treated groups.  The 
fluorescence intensity of Syk within SGs decreased significantly with PP1 
treatment while the fluorescence intensity of G3BP within these same puncta did 
not change (Fig. 5.15).  These results are consistent with a contribution of Src-
family kinases to the recruitment of Syk to SGs, likely through the 
phosphorylation of Syk on Y342 and Y346.    
 
5.5 Syk is recruited to SGs by Grb7 
 The requirement for two linker B tyrosines for the recruitment of Syk to 
SGs suggested a role for an adaptor protein that could bind to Syk when it is 
phosphorylated on both Y342 and Y346.  To identify potential adapters we 
performed a yeast two-hybrid screen using as prey a human mammary gland 
cDNA library and, as bait, both an active and a catalytically inactive form of Syk.  




Syk becomes tyrosine-phosphorylated in yeast while the catalytically inactive 
mutant does not.34 Several proteins containing SH2 or functionally related 
domains were identified that bound selectively to active Syk, but not to the 
catalytically inactive mutant (Fig. 5.16).  These included Grb7, Grb10, Cbl-3, 
Vav3, Crk, and Shc. Of these, only Grb7 had been identified previously as a 
component of SGs.45  In the yeast two-hybrid screen, Grb7 bound to full-length 
Syk, failed to bind to the catalytic domain of Syk or to the tandem pair of SH2 
domains, but was capable of binding to a construct containing both the linker B 
region plus the catalytic domain, consistent with an interaction mediated by 
residues within linker B. To explore this further, we performed an in vitro pull-
down assay in which the immobilized GST-SH2 domain of Grb7 was incubated 
with lysates of MCF7-BD cells expressing either wild-type Syk-EGFP or Syk-
EGFP(Y342F/Y346F).  As shown in Fig. 5.17A, the SH2 domain of Grb7 
preferentially interacted with the wild-type kinase, supporting a role for Y342 and 
Y346 in the association Syk with Grb7.  To confirm the localization of Grb7 to 
SGs, we treated MCF7-BD cells expressing Syk-EGFP with MG132 and then 
stained cells with antibodies against TIAR and endogenous Grb7.  Fractions of 
both Syk-EGFP and Grb7 relocated into the detergent insoluble fraction of 
MCF7-BD cells following their treatment with MG132 (Fig. 5.17B).  In addition, 
endogenous Grb7 could be co-immunoprecipitated with G3BP selectively under 
conditions that promoted the formation of SGs; and this interaction did not 








In contrast, the association of Syk with Grb7 did not require SG formation (Fig. 
5.19).  Both Syk and Grb7 proteins localized to cytoplasmic puncta that also 
contained TIAR (Fig. 5.20). 
 To investigate further if the SH2 domain of Grb7 was involved in the 
recruitment of Syk to SGs, we inactivated the domain by mutating the essential 
arginine in the canonical phosphotyrosine binding site to a methionine.  Wild-type 
Grb7 with an mCherry tag at the C-terminus (Grb7-mCherry) and Grb7-
mCherry(R451M) were transiently expressed in MCF7-BD cells expressing Syk-
EGFP, which were then treated with MG132 to induce SG formation.  While wild-
type Grb7-mCherry localized to SGs along with Syk-EGFP and TIAR.  Neither 
Grb7-mCherry(R451M) nor Syk-EGFP localized to TIAR-containing SGs (Fig. 
5.21A and 5.21B).  Thus, a functional SH2 domain of Grb7 promotes the 
recruitment of both Syk and Grb7 to SGs.   
 
5.6 Syk promotes the clearance of SGs 
 We compared the number of SGs formed in MDF7-BD cells expressing or 
lacking Syk-EGFP following a 3 hour treatment with MG132.  The number of SGs 
formed per cell was on average higher in Syk-deficient cells than in cells stably 
expressing Syk-EGFP (Figure 5.22).  This suggested a role for Syk in modulating 
SG dynamics.  To explore this further, we examined the effect of Syk on the 
ability of cells to clear SGs following their release from the stress stimulus.  
MCF7-BD cells expressing Syk-EGFP or lacking Syk were treated with MG132 






drug-free media for 4 hours.  Cells were then fixed and immunostained with an 
antibody against G3BP to detect SGs.  The number of cells containing >3 SGs 
were counted as SG positive (SG+) while those with 3 or fewer SGs were 
counted as SG negative.  The presence or absence of Syk in MCF7-BD cells had 
little influence on the number of SG+ cells formed during the initial 3-hour 
incubation.  However, far fewer Syk-EGFP-expressing cells retained SGs 
following the four-hour recovery period as compared to cells lacking Syk (Fig. 
5.23).  To confirm this observation, we performed a biochemical assay to assess 
changes in the level of phospho-eIF2  by Western blot analysis.  In MCF7-BD 
cells, the induction of SGs with MG132 resulted in an increase in the extent of 
phosphorylation of eIF2  in both Syk-expressing and Syk-deficient cells (Fig. 
5.24).  However, the level of phospho-eIF2  decreased to a greater extent 
following the four-hour recovery phase in cells expressing Syk-EGFP than in 
cells lacking the kinase, consistent with the presence of fewer SGs. 
 To assess whether the catalytic activity of Syk was necessary for SG 
clearance, we compared Syk-deficient MCF7-BD cells to those stably expressing 
either Syk-AQL-EGFP or Syk-EGFP.  Cells were treated with MG132 for three 
hours to induce SG formation and were then washed and allowed to recover in 
fresh media for four hours.  Where indicated, an orthogonal inhibitor of Syk-AQL, 
3-MB-PP1, was added either immediately following the removal of MG132 or one 
hour later (Fig. 5.25A and 5.25B).46  Cells were fixed, stained using a G3BP 
antibody, and examined for the presence of SGs.  As observed previously, most 






In contrast, most cells expressing either Syk-EGFP or Syk-AQL-EGFP were 
largely free of visible SGs 4 hours after removal of the MG132.  The addition of 
3-MB-PP1 had no effect on this reduction in SGs in the Syk-EGFP-expressing 
cells, but effectively blocked the clearance of SGs from cells expressing Syk-
AQL-EGFP.  When 3-MB-PP1 was added one hour after the removal of MG132, 
the number of Syk-AQL-EGFP-expressing cells that were SG+ was reduced by 
approximately 50%. Thus, many cells were able to clear most SGs in the first 
hour following removal of MG132, but further clearance could be blocked by a 
kinase inhibitor.     
 To determine if the association of Syk with SGs also was required for their 
clearance, we compared MCF7-BD cells stably expressing Syk-EGFP to those 
expressing Syk-EGFP(Y342F/Y346F), which is catalytically active, but fails to 
associate with SGs.  Cells again were treated with MG132 for 3 hours and then 
washed and allowed to recover for 4 hours.  The number of SG+ cells was much 
higher for those expressing Syk-EGFP(Y342F/Y346F) as compared to those 
expressing wild-type Syk-EGFP (Fig. 5.26).  Thus, both the catalytic activity of 
Syk and its association with SGs are required for the clearance of SGs from cells 









5.7 SGs are cleared through autophagy 
 Recent data indicate that SGs can be cleared from cells through the 
process of autophagy.20  To determine if autophagy was involved in the Syk-
dependent clearance of SGs, we treated MCF7-BD cells stably expressing Syk-
EGFP with MG132 for 3 hours to induce SG formation.  Cells were washed and 
allowed to recover in the absence of MG132, but in the presence of one of two 
known inhibitors of autophagy: DBeQ or 3-MA.  Cells were then fixed and stained 
with a G3BP antibody to detect SGs.  Both autophagy inhibitors blocked the 
ability of Syk-EGFP to promote SG clearance in cells recovering from MG132-
induced stress (Fig. 5.27).   
 Since cells expressing Syk-EGFP effectively cleared SGs while cells 
lacking Syk did not, we compared MCF7-BD cells expressing or lacking the 
kinase for the formation of autophagosomes during recovery from MG132-
induced stress.  Cells were treated with MG132 for 3 hours, washed and allowed 
to recover for 4 hours in the absence of the proteosome inhibitor.  Cells were 
fixed and stained for LC3, a protein that is processed and incorporated into 
maturing autophagosomal membranes and thus serves as a useful marker for 
these vesicles.47  Abundant LC3-positive vesicles were observed in cells 
expressing Syk-EGFP as opposed to cells lacking Syk, which exhibited few 
autophagosomes (Fig. 5.28).  To determine if the association of Syk with SGs 
also was important for autophagosome formation, we compared MCF7-BD cells 
expressing Syk-EGFP to those expressing Syk-EGFP(Y342F/Y346F).  Cells 





LC3-positive vesicles were much more plentiful in the Syk-EGFP-expressing 
cells as compared to cells expressing Syk-EGFP(Y342F/Y346F) (Fig. 5.29).  
These results indicate that the recruitment of Syk to SGs promotes their 
clearance through the recruitment or formation of autophagosomes in a process 
that requires the catalytic activity of the kinase.   
 
5.8 SG clearance promotes cell survival 
 Since Syk functions as a pro-survival factor in numerous cancer cell types, 
we asked if the expression of the kinase might alter the capacity of cells to 
survive an insult that results in the formation of SGs.4  MCF7-BD cells expressing 
Syk-EGFP or lacking Syk were treated with low concentrations of sodium 
arsenite for 3 hours, conditions under which cells formed numerous small SGs.  
Cells were washed and then allowed to recover and proliferate in fresh media for 
24 hours.  Cell survival/proliferation was then measured using the MTT assay.  
While cells expressing Syk grew normally following removal of the stress 












 Our study supports a model in which Syk is recruited to SGs that are 
induced in response to external agents that cause oxidative stress and disrupt 
protein folding or interfere with the ubiquitin-proteosome system.  This 
recruitment requires the phosphorylation of Syk on a pair of tyrosines in the linker 
B region, which creates a docking site for the SG component, Grb7.  Once at the 
SG, Syk is active and catalyzes the phosphorylation of proteins on tyrosine that 
promote the clearance from the cell of SGs through autophagy, thus enabling the 
cells to recover from the initial stress stimulus.   
 The recruitment of Syk to SGs requires its phosphorylation on the two 
tyrosines found within the sequence, YESPYADP.  Multiple proteins have been 
described that contain SH2 domains capable of binding within this region; and 
many of these SH2 domains recognize Syk preferentially when both tyrosines 
(Y342 and Y346) are phosphorylated.48,49  This was first demonstrated for the C-
terminal SH2 domain of phospholipase PLC-g (PLCC).48  In this case, 
phosphotyrosine-342 binds in the canonical phosphotyrosine binding pocket 
found within all SH2 domains while phosphotyrosine-346 binds at a second site 
found only in a subset of SH2 domains.  Here the phosphate group interacts with 
two critical lysines.  Interestingly, these two lysines are conserved in the 
sequence of the Grb7.  The expression of a form of Grb7 with an SH2 domain 
disabled by a point mutation blocks the recruitment of Syk to the SG consistent 
with an SH2 domain-mediated interaction between Syk and Grb7.  Unexpectedly, 
the association of Grb7 with the SG also is inhibited by this mutation.  This 
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suggests that the Grb7 SH2 domain is important for both its interaction with Syk 
and with SGs.  This may reflect the fact that both Grb7 and its isolated SH2 
domain are dimers, capable of binding simultaneously more than one ligand.50,51  
The site or sites on the SG to which the Grb7 SH2 domain binds is not known, 
nor is it known whether or not this site contains phosphotyrosine as the Grb7 
SH2 domain is capable also of recognizing amino acid sequences that lack a 
phosphoamino acid.52,53   
 The ability of a catalytically inactive form of Syk to associate with SGs 
suggests that the phosphorylation of Y342 and Y346 can be catalyzed by 
kinases other than Syk itself.  This is consistent with previous phosphopeptide 
mapping experiments demonstrating the phosphorylation of catalytically inactive 
Syk on Y342 and Y346 in B cells activated through the antigen receptor in a 
manner dependent on the expression of Lyn, a Src-family kinase.44 Consistent 
with this idea, the inclusion of a Src-kinase inhibitor reduced the content of Syk in 
SGs.  Interestingly, Src kinases also are known to phosphorylate at least one 
other SG component, Sam68/KHDR1.10,54   
 We find that the presence of Syk in MCF7 cells is not required for the 
formation of SGs. In fact, the number of SGs present in Syk-expressing cells 
treated for 3 hours with MG132 is reduced compared to the number in cells 
lacking the kinase.  The presence or absence of Syk, however, does have a 
dramatic effect on the disappearance of SGs from cells once the stress is 
removed.  This clearance of SGs requires the association of Syk with the SG, as 
Syk-EGFP(Y342F/Y346F) fails to promote SG clearance.  The addition of an 
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inhibitor orthogonal to Syk-AQL-EGFP to cells expressing Syk-AQL-EGFP, but 
not to cells expressing Syk-EGFP, also blocks SG clearance.  This indicates an 
essential and specific role for Syk-catalyzed tyrosine phosphorylation in this 
process.  Visualization of protein-tyrosine phosphorylation by 
immunofluorescence clearly demonstrates a substantial increase in the 
phosphorylation of proteins resident in or near SGs.  This phosphorylation is 
largely Syk-dependent as it is selectively blocked in cells expressing Syk-AQL-
EGFP upon treatment with the Syk-AQL-specific inhibitor.  However, the exact 
protein or proteins that Syk phosphorylates to promote SG clearance remains to 
be determined.   
 SGs are thought to disassemble following the removal of stress, allowing 
sequestered mRNAs to return to ribosomes for translation.11  A recent genetic 
screen in yeast, however, clearly indicates a critical role for components of the 
autophagy pathway in modulating the dynamics of SG removal.20 Consistent with 
a role for autophagy in SG dynamics in MCF7 cells, the addition of inhibitors of 
autophagy clearly blocks the Syk-dependent clearance of SGs in cells following 
removal of the stress stimulus.  Also consistent with this mechanism, a 
substantial increase in LC3-positive vesicles is seen in cells recovering from 
stress when cells contain a catalytically active form of Syk that also is capable of 
binding to SGs.  These observations clearly implicate Syk as an important factor 
in regulating the removal from cells of SGs through autophagy.  Grb7, which 
promotes SG formation or enhances SG stability, has been reported also to 
recruit to SGs focal adhesion kinase (FAK), which phosphorylates G4b7 to 
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promote SG disassembly.45  It is not known if autophagy contributes to the loss of 
SGs that is seen following the recruitment of FAK and phosphorylation of Grb7. 
 The consequences of the presence or absence of Syk in tumor cells are 
manifested in different ways depending on the tumor cell type and its stage of 
development.4  In many tumors, the expression of Syk enhances cell survival, 
especially in the face of external or internal factors including oxidative stress, 
exposure to chemotherapeutic agents, expression of oncogenes like activated K-
Ras or loss of Rb.4,5,8,9  Multiple mechanisms have been described to account for 
many of Syk’s protective effects on cells including activation of the PI3K/Akt pro-
survival pathway leading to the stabilization of the anti-apoptotic proteins Mcl-1 
and/or XIAP, activation of mTOR, activation of STAT3 or STAT5, enhanced 
transcription of NF-kB-regulated genes, and stabilization of the mRNA for Bcl-xL 
through an association of Syk with nucleolin.8,9,55-61  The contributions of 
autophagy to cancer cell survival also are context dependent. While a lack of 
autophagy can contribute to tumorigenesis in some cancer types, in some 
established tumor cells autophagy instead confers a survival advantage that is 
particularly important for the cancer cell resistance to external stresses including 
hypoxia and exposure to radiation or chemotherapeutic agents.24-27  Thus, many 
established tumors rely on autophagy as a mechanism to survive elevated 
metabolic or therapeutic stress; and inhibitors of autophagy can sensitize some 
tumors to the actions of chemotherapeutic agents.26  MCF7 cells are relatively 
insensitive to the inhibition of autophagy for basal cell growth.62  However, we 
find that MCF7 cells expressing Syk are better able to recover from exposure to 
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sodium arsenite, which induces SG formation, than are cells lacking the kinase.  
This suggests that the increased autophagy promoted by the presence of Syk 
facilitates cell survival in response to stress.  Thus, Syk-dependent enhancement 
of autophagy provides an additional mechanism by which the kinase can enable 
cancer cells to evade stress-induced cell death.  This suggests that Syk inhibitors 
would be useful in sensitizing a subset of Syk-expressing cancer cells to the 
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 Future studies could be directed toward exploring the molecular 
mechanisms by which Syk modulates cytoskeletal networks and determining how 
Syk regulates autophagy.  Several questions could be addressed including 1) 
how Syk-dependent phosphorylation of other microtubule-associated proteins 
affects cytoskeletal properties and 2) how Syk regulates aggresome and stress 
granule clearance through autophagy. 
 
6.2 Syk-dependent phosphorylation of MAPs and cytoskeletal properties 
 For microtubules to maintain their dynamic functions, they rely on a variety 
of microtubule-stabilizing proteins and other microtubule-associated proteins.  
Interestingly, a number of microtubule-associated proteins were identified in our  
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mass spectrometry analyses of Syk substrates.1-3 Among these were EB1, 
MAP1B, and FOP, which were all identified as being phosphorylated in a Syk-
dependent manner. We observed that Syk functions through MAP1B to promote 
microtubule stability; however, this change in stability was not entirely due to 
MAP1B.4  MDA-MB-231 cells treated with shRNA to knockdown MAP1B were 
less stiff and more elastic compared to cells that expressed endogenous MAP1B.  
However, the MDA-MB-231 cells with reduced MAP1B were still more stiff and 
less elastic than the cells lacking endogenous Syk.4 This suggests that other 
microtubule-associated proteins help to regulate microtubule stability in a Syk-
dependent manner even when MAP1B protein is absent.  Alternatively, Syk may 
regulate other cytoskeletal networks like actin polymers to stabilize microtubules 
in conjunction with MAP1B.   
 The EB1-protein family includes EB1, RP1, and EBF3.  EB1, like other 
family members, localizes to microtubule tips and has been used as a marker for 
microtubule ends and to track microtubule dynamics. 5 It also has been shown to 
interact with the dynactin complex, which activates dynein motor proteins 
associated with microtubules.6 EB1 has been shown to have an important role in 
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cell polarity maintenance by its association with microtubules and through linking 
this association to actin protrusion, thus facilitating the cross-talk between these 
cytoskeletal networks.7   It is hypothesized that PKC-  phosphorylates EB1 and 
that this phosphorylation aids EB1’s contribution to cellular polarity.7  EB1 also 
has been shown to localize on astral microtubules, and enhance their stability.7  I 
performed a shRNA knockdown targeting EB1 protein in MDA-MB-231 cells 
stably expressing Syk-EGFP.  However, I observed that Syk still stabilized 
microtubules when cells were treated with nocodazole even in the absence of 
EB1.  Thus, it appeared that in MDA-MB-231 cells, EB1 was not responsible for 
Syk’s ability to stabilize microtubules 
 FGFR1 oncogene partner (FOP) was first discovered as a fusion partner 
of FGFR1 that occurred by a t(6;8) translocation in stem cell myeloproliferative 
disorders.8  The chimeric protein localized to the centrosome where the FGFR1 
kinase domain initiated phosphorylations that led to deregulation of the cell 
cycle.8-10 The normal role of FOP is to anchor microtubules to the centrosome.11  
Its interaction with CAP350 maintains its association with the centrosome.  In 
addition, FOP is required for the recruitment of EB1 protein to the centrosome.11  
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I generated MDA-MB-231 cell line with knockdown of FOP using a lentiviral  
shRNA  delivery system that targeted FOP.  Cells in which FOP protein was 
knocked down had a less dense microtubule network emanating from the 
centrosome as compared to cells expressing endogenous FOP protein, 
consistent with a role for FOP in anchoring microtubules to the centrosome.  
Interestingly, the treatment of FOP-knockdown cells with nocodazole resulted in 
a pronounced blebbing phenotype that was enhanced in cells expressing Syk. 
This blebbing was inhibited by a ROCK (Rho-associated protein kinase) inhibitor 
suggesting a role for Syk also in modulating actin-myosin dynamics. It would be 
interesting to investigate further the pathways through which Syk modulates the 
properties of the actin cytoskeleton in cancer cells. 
 Cellular blebbing is one mechanism of motility.  In 2003, it was shown that 
cancer cells that invade through a 3D collagen matrix under conditions in which 
matrix degradation is blocked do so through an amoeboid mode of invasion 
involving the formation of bleb-like constriction rings.12  It appears that cancer 
cells use this amoeboid mode of invasion to bypass the requirement for 
extracellular matrix proteolysis as an alternative way to metastasize.12 Cellular 
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blebbing has been identified in many cancer cell lines including melanoma and T-
cell lymphoblastic leukemia.13-14  The mechanisms that promote blebbing are 
ROCK dependent.  Intra or extracellular signals can initiate the conversion of 
RhoA-GDP to RhoA-GTP, and this results in the formation of a ROCK1, 3-
phosphoinositide-dependent protein kinase (PDK1), and RhoA-GTP complex.  
ROCK1 phosphorylates myosin light chain (MLC) phosphatase and promotes 
acto-myosin contractility leading to blebbing.  Deficiencies in the actin-binding 
proteins filamin A and talin have been shown to induce blebbling,15 but depletion 
of FOP and its effects on cellular blebbing have not been investigated.   
 Further investigations into how Syk influences FOP-dependent blebbing 
through the ROCK pathway would be of interest.   Future studies could evaluate 
whether Syk-dependent phosphorylation sites on FOP affect its ability to anchor 
microtubules to the centrosome or form complexes with CEP350 and/or EB1, 
and determine whether or not phosphorylation influences blebbing.  Motility 
assays could also be performed using 3D cultures to investigate if these blebs 
promote invasion. Biochemical analyses could also be performed to investigate 
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whether RhoA activation and MLC phosphorylation occur in cell lines where FOP 
protein expression is reduced. 
 
6.3 How does Syk regulate aggresomes and stress granule clearance through 
autophagy and the cytoskeleton 
 Autophagy has been shown to be important in clearing protein aggregates 
accumulated in both stress granules and aggresomes. Aggresomes are 
aggregated puncta of misfolded proteins.16  We have identified that, under 
various stress conditions, Syk can either localize to stress granules and 
potentially also with aggresomes.  We have identified a number of proteins 
through mass spectrometry analyses that are involved in the export of misfolded 
proteins from the ER to the cytoplasm including valosin-containing protein (VCP), 
valosin-containing protein (P97)/P47 complex interacting protein 1 (VCPIP1), N-
ethylmaleimide-sensitive factor and valosin-containg protein (NSFL1C), ubiquitin 
fusion degradation protein 1 homolog (UFD1L), and nuclear protein localization 4 
homolog (NPLOC4).  Interestingly, VCP has been shown to be critical for 
autophagy and can impair the formation and clearance of stress granules and the 
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clearance of protein aggregates.17,18 Stress granule clearance is important to 
maintain cellular homeostasis especially since the accumulation of protein 
aggregates can lead to neurodegenerative disease.  Lou Gehrig’s disease (ALS) 
is a motor neuron degenerative disease.  One of the pathological hallmarks in 
this disease is the presence of puncta containing TAR DNA-binding protein 43 
(TDP-43), which is a protein that colocalizes with stress granules in degenerating 
neurons.19 VCP has been shown to form a complex with VCPIP1, UFD1L, and 
NPLOC420 and mutations in VCP are known to cause familial ALS.21 Therefore, I 
hypothesize that the clearance of stress granules and aggresomes by autophagy 
could be regulated through the phosphorylation of these factors and thus 
modulation of complex formation and/or function.  First, to test whether 
endogenous VCP interacts with the Syk complex, immunoprecipitation of VCP 
followed by a Western blot using antibodies for Syk could be performed.  Next, if 
these two proteins are in a complex together, then various phosphorylation site 
mutants of VCP could be expressed in cells stably expressing Syk to evaluate 
whether phosphorylation of VCP modulates complex formation and autophagy.  
Ultimately knockdown studies using shRNAs targeting UFD1L and NPLOC4 
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could be performed to evaluate if either of these proteins are critical components 
required for the clearance by autophagy of either stress granules or aggresomes.  
Furthermore, EB1 has been linked to the absent melanoma 2 protein (AIM2) 
complex involved in inflammasome formation and is required for autophagy-
dependent secretion of IL1- .22 It would be interesting to determine if EB1 is an 
important participant in the process by with stress granules or aggresomes are 
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